header logo image


Page 765«..1020..764765766767..770780..»

How Colds Are Unlocking Secrets About Life on Other Planets – Sciworthy

January 3rd, 2020 8:42 am

Scientists from the University of Zurich and the Max Planck Institute for Molecular Genetics, as well as the Icahn School of Medicine at Mount Sinai have come together to summarize recent evidence has challenged our working theory on the origin of life. Previously, scientists thought early life may have arisen from proteins or other chemical reactions important for life reacting in the hot soup of early Earth before there were actually cells. Then, it has been thought that these chemical reactions may have later been taken over by early cells.

However, long ago, after discovering large amounts of amino acids, DNA, and RNA on meteorites in our cosmic neighborhood, researchers again had to shift their train of thought. This paper explained that experiments that mimicked the temperature, acidity, pressure, and energy of an Early earth provided evidence that life may have come from random assortments of RNA and other small molecules. Then, the authors continued, a hypothesis was developed that RNA may have been the primordial first lifeform which took shape on our planet and may have already formed on others. The authors claim that this led to this most recent and widely accepted theory: our world may have been a RNA world at one point in its development; one in which life was composed of a few self-reproducing RNA molecules that worked to spread information as rapidly as possible and combined with amino acids to make proteins which could assist it. The problem with this idea is that researchers are still struggling to engineer RNA molecules that create themselves; a necessary condition if RNA is to reproduce and be able to evolve. Enter the viroid viroids are, essentially, a piece of RNA that can copy itself. Viroids can also insert themselves into a hosts DNA using normal cell processes.

A study highlighted in this article attempted to imitate RNA. Researchers showed that, in solutions of rich in salts and sugars, RNA can spontaneously regrow quite rapidly. These molecules were able to reproduce across 74 generations. From looking at how the sequences changed over these generations, it was determined that viroids replicated fast and continually became smaller and smaller strands of RNA.

The authors conclude that, given what we know about viroids, the idea of a viroid-first origin-of-life theory should be seriously considered, though there is not yet enough evidence to be confident. The good news is that detecting small organic molecules and viroid particles in the depths of space and below the surface of other planets is a lot easier to do than finding evidence to support other origin of life theories, since this theory uses techniques and science that are already familiar to biologists. Genetic engineers are still struggling to create self-copying RNA outside of a viroid-like model and proteins and metabolic chemicals havent turned up in our observations of the space beyond our solar system.

Evidence of organic molecules such as pieces of RNA, DNA, and proteins have been found on recent meteorites. This demonstrates that space already has the conditions to allow for these chemical reactions to take place beyond Earth. The authors suggest that the beginning of life must have been simple, and the search for signatures of viruses, viroids, and small RNA and the modeling of these life forms may be where we need to turn our attention next to answer the questions about life in our Universe.

View post:
How Colds Are Unlocking Secrets About Life on Other Planets - Sciworthy

Read More...

Global Human Microbiome Markets (2019-2030), Drugs, Companies, Therapeutics, Diagnostics, Case Studies, Executive Insights, and More – PRNewswire

January 3rd, 2020 8:42 am

DUBLIN, Jan. 3, 2020 /PRNewswire/ -- The "The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based medical products (including therapeutics, diagnostics and FMTs), over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved / late stage (estimated) microbiome therapeutics, diagnostic products and FMTs.

The report also features the likely distribution of the current and forecasted opportunity within microbiome therapeutics market across:

In addition, it also features the likely distribution of the current and forecasted opportunity within microbiome diagnostics market across:

In addition to other elements, the study includes:

In order to account for the uncertainties associated with the growth of microbiome market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Chapter Overview3.2. Concept of Microbiota and Microbiome3.3. Overview of Gut Flora3.4. The Microbiome and Disease3.5. Impact of Microbiota on Drug Pharmacokinetics3.6. Impact of Microbiota on Therapeutic Outcomes3.7. Microbiome Therapeutics3.8. The Human Microbiome Project (HMP)3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)3.10. Key Challenges in the Development of Microbiome Therapeutics3.11. Future Perspectives

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE4.1. Chapter Overview4.2. Microbiome Therapeutics: Clinical Pipeline4.3. Microbiome Therapeutics: Early-Stage Pipeline4.4. Microbiome Therapeutics: List of Drug Developers4.5. Microbiome Therapeutics: List of Discontinued Drugs4.6. Emerging Role of Microbiome in Gut-Brain Axis4.7. Microbiome Therapeutics: List of Technology Platforms

5. COMPANY AND DRUG PROFILES5.1. Chapter Overview5.2. 4D Pharma5.3. Armata Pharmaceuticals5.4. Evelo Biosciences5.5. Rebiotix (Acquired by Ferring Pharmaceuticals)5.6. Seres Therapeutics5.7. Vedanta Biosciences

6. MICROBIOME DIAGNOSTICS: MARKET LANDSCAPE6.1. Chapter Overview6.2. Overview of Microbiome Diagnostic Tests6.3. Microbiome Diagnostic Tests: Marketed and Under Development Products6.4. Microbiome Diagnostic Tests: List of Diagnostic Developers6.5. Profiles of Prominent Diagnostic Developers6.6. Overview of Microbiome Screening / Profiling Tests

7. FECAL MICROBIOTA THERAPY (FMT)7.1. Chapter Overview7.2. Introduction to FMT7.3. Historical Overview7.4. FMT: Procedure and Clinical Relevance7.5. Regulatory Guidelines Related to FMT7.6. Insurance Coverage for FMT7.7. FMT: Competitive Landscape7.8. Clinical Trial Analysis (Non-Industry Sponsored)7.9. Stool Banks

8. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX8.1. Chapter Overview8.2. AC Matrix: An Overview8.3. AC Matrix: Analytical Methodology8.4. AC Matrix: Plotting the Information8.5. AC Matrix: Analyzing the Data8.6. Concluding Remarks

9. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS9.1. Chapter Overview9.2. Scope and Methodology9.3. Initiatives of Big Pharmaceutical Players9.4. Benchmark Analysis of Big Pharmaceutical Players

10. START-UP HEALTH INDEXING10.1. Chapter Overview10.2. Scope and Methodology10.3. Benchmark Analysis of Start-ups

11. KEY THERAPEUTIC AREAS11.1. Chapter Overview11.2. Metabolic Disorders11.3. Digestive and Gastrointestinal Disorders11.4. Oncological Indications11.5. Dermatological Disorders11.6. Infectious Diseases

12. FUNDING AND INVESTMENT ANALYSIS12.1. Chapter Overview12.2. Types of Funding12.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments12.4. Concluding Remarks

13. CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS13.1. Chapter Overview13.2. Manufacturing Microbiome Therapeutics13.3. Microbiome Therapeutics-related R&D13.4. Key Considerations for Selecting a Suitable CMO / CRO Partner

14. BIG DATA AND MICROBIOME THERAPEUTICS14.1. Chapter Overview14.2. Introduction to Big Data14.3. Internet of Things14.4. Growing Interest in Big Data: Google Trends Analysis14.5. Key Application Areas14.6. Big Data in Microbiome Research14.7. Big Data Services for Microbiome Research: List of Companies14.8. Big Data Services for Microbiome Research: Profiles of Key Players

15. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS15.1. Chapter Overview15.2. Scope and Limitations15.3. Forecast Methodology15.4. Overall Microbiome Therapeutics Market, 2019-203015.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2019-2030

16. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS16.1. Chapter Overview16.2. Scope and Limitations16.3 Forecast Methodology16.4. Overall Microbiome Diagnostics Market, 2019-203016.5. Microbiome Diagnostics Market: Distribution by Target Indications, 2019-203016.6. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-203016.7. Microbiome Diagnostics Market: Distribution by Supply Channel, 2019-203016.8. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030

17. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS17.1. Chapter Overview17.2. Scope and Limitations17.3. Forecast Methodology17.4. Overall FMT Market, 2019-203017.5. Overall Microbiome Market by Product Offerings, 2019-2030

18. CASE STUDY: MICROBIOME-BASED PRODUCTS IN OTHER INDUSTRIES18.1. Chapter Overview18.2. List of Microbiome Products in Other Industries18.3. Applications of Microbiome Based Products in Agriculture Industry18.4. Future Prospects

19. CONCLUDING REMARKS

20. EXECUTIVE INSIGHTS20.1 Chapter Overview20.2. Rebiotix20.3. S-Biomedic20.4. Whole Biome20.5. Siolta Therapeutics20.6. OpenBiome20.7 Assembly Biosciences20.8. List Biological Laboratories20.9. Metabiomics20.10. MicroBiome Therapeutics20.11. Universal Stabilization Technologies20.12. BiomX20.13. Da Volterra20.14. Chung Mei Pharmaceutical20.15. Pacific Northwest National Laboratories

21. APPENDIX I: TABULATED DATA

22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/sakzqu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Continue reading here:
Global Human Microbiome Markets (2019-2030), Drugs, Companies, Therapeutics, Diagnostics, Case Studies, Executive Insights, and More - PRNewswire

Read More...

Atrium Innovations to Further Scale the Future of Personalized Nutrition with the Acquisition of LivingMatrix – PRNewswire

January 3rd, 2020 8:41 am

SUDBURY, Mass., Jan. 3, 2020 /PRNewswire/ --AtriumInnovations, a globally-recognized leader in the development, manufacturing, and commercialization of innovative, science-based nutritional health products, takes the next step in the company's mission to expand into personalized nutrition with the acquisition of San Francisco-based LivingMatrix.LivingMatrix, a technology-based, data and algorithm-driven personalized functional medicine platform, was designed by clinicians to help practitioners effectively evaluate and engage patients, create personalized, actionable care plans and track patient health outcomes.

"This exciting acquisition is reflective of the current mission and direction for Atrium Innovations, with support from Nestl Health Science, to expand our role in personalization within the medical professional and consumer spaces. The addition of LivingMatrix will allow us to take the next steps in leading the future of personalized health management," says Kyle Bliffert, President of Atrium Innovations. "Our goal is to further scale our personalization platform through integrating LivingMatrix with our existing PureGenomics platform and future healthcare provider patient management systems providing the most comprehensive solution in the industry."

"The addition of LivingMatrix to the Atrium Innovations growing personalized medicine portfolio will further elevate the way functional medicine practitioners and patients in our longstanding network view and use healthcare," adds Joy Devins, Chief Strategic Leader of Atrium Innovations.

"The launch of the LivingMatrixplatform has been a critical turning point for personalized and functional medicine and now, with the support of the Atrium Innovations and Nestl Health Science family, we look forward to breaking even more barriers," says Priya Kamani, Founder and CEO of LivingMatrix. "This partnership brings opportunities to scale the business and accelerate our ability to drive and support additional research studies to expand the evidence base for effectively addressing chronic conditions."

LivingMatrixis the latest acquisition for Nestl Health Science as part of the company's mission to lead the personalized nutrition sector into its next evolution. Their recent acquisition of Persona, a science-based proprietary technology which considers specific factors in a consumer's lifestyle, history and individual needs to develop a personalized vitamin program, was announced in August 2019. Persona's individualized assessments meet consumers' desires to find the right nutritional supplements for their unique needs. These personalized vitamin and supplement services are available to consumers through http://www.personanutrition.com. These strategic acquisitions will leverage Atrium Innovations' nearly 30-year industry expertise, bringing valuable insight from the company's network of medical professionals as well as professional brand development knowledge to the partnership.

"Through combining the strength of Persona's proprietary algorithm, the LivingMatrix data-driven technology and Atrium Innovation's leadership in the industry, we are creating an exciting future for personalized nutrition for professionals and consumers alike," says Bliffert.

For more information about Atrium Innovations, visit http://www.atrium-innovations.com.

About Nestl Health Science (NHSc)Nestl Health Science (NHSc), a wholly-owned subsidiary of Nestl, is a globally recognized leader in the field of nutritional science. NHSc is committed to empowering healthier lives through nutrition for consumers, patients and their healthcare partners. The company offers an extensive consumer health portfolio of industry-leading medical nutrition, consumer and VMS brands that are science-based solutions covering all facets of health from prevention, to maintenance, all the way through to treatment. NHSc is redefining the approach to their management of health in several key areas such as pediatric health, allergy, acute care, oncology, metabolic health, healthy aging, gastrointestinal health, and inborn errors of metabolism. Headquartered in Switzerland, NHSc employs over 5,000 people around the world, who are committed to making a difference in people's lives, for a healthier today and tomorrow. For more information, visit https://www.nestlehealthscience.com.

About Atrium Innovations Atrium Innovations is a recognized innovative leader in the development, manufacturing, and commercialization of science-based nutritional and supplement health products. The company's mission is to be a global leader in vitamins, minerals and supplements, offering free form science based nutritional solutions through healthcare professionals. Its brands and business model are complementary with Nestl Health Science, its parent company, offering science-based nutritional solutions for consumers, patients, doctors, nurses and other partners in healthcare. Atrium Innovations Professional brands include Pure Encapsulations, Douglas Laboratories, Genestra BrandsTM, KLEAN Athlete, PharmaxTM, and Wobenzym.

About LivingMatrixLivingMatrix is the leading cloud-based, clinician-designed, outcomes-focused personalized medicine platform, helping over 600 practices in 22 countries engage in high-quality, personalized, therapeutic partnerships to address chronic conditions at scale effectively. LivingMatrix has partnered with the Institute for Functional Medicine and helps practitioners deliver a unique engagement process utilizing the Timeline and Matrix tools, and validated, patient-reported outcomes measures that provide a comprehensive assessment of a patient's health and objective tracking of patient progress. The result is a faster time to life-changing outcomes for the patient and an increase in referrals and growth for the practice. Learn more at https://livingmatrix.com

About Persona Persona combines therapeutic levels of nutritional support and a uniquely personalized vitamin program to deliver customized nutrition to subscriber's doorsteps. Based on science and using the highest-quality bioavailable ingredients, Persona's online assessment is built from its proprietary algorithm, which factors individual needs, lifestyle and prescription medications to deliver a recommendation as unique as the patient providing 5 trillion different recommendations. https://www.personanutrition.comInstagram:@personanutrition

Media Contact:Ashley HughesRLA Collective, a Ruder Finn Company(914) 241-0086, ext. 1014Ashley.Hughes@RLACollective.com

SOURCE Atrium Innovations

Nutritional health products EMPOWERING HEALTHIER LIVES

Read the original here:
Atrium Innovations to Further Scale the Future of Personalized Nutrition with the Acquisition of LivingMatrix - PRNewswire

Read More...

Understanding the Key Aspects of a Multiple Myeloma Diagnosis – Curetoday.com

January 3rd, 2020 8:41 am

A multiple myeloma expert helps newly diagnosed patients understand the standard of care for their disease.

Richter, an assistant professor of medicine at the Tisch Cancer Institute at the Ichan School of Medicine in Mt. Sinai Hospital located in New York City, noted that there are always exceptions to this rule, but the standard of care is to keep patients with multiple myeloma to continue therapy long term.

This standard of care, however, presents unique challenges and questions for newly diagnosed patients about to undergo treatment. In an interview during the 2019 CURE Educated Patient Summit on Multiple Myeloma in Charlotte, North Carolina, Richter had the chance to address the key aspects of a multiple myeloma diagnosis and how he addresses common questions from patients.

CURE: What does transplant eligible and transplant ineligible mean for patients?

Richter: The notion of transparent eligibility in the U.S. is not clearly defined. One of the people who trained me used to say, Do the patients have the tiger? relating back to Rocky, and essentially what this means is people who are younger tend to be more eligible. So, are you able to undergo the intensive nature of that procedure and chemotherapy?

If you're younger and healthier, you're generally transplant eligible. As you get older, with more medical problems, it becomes more of a risk. Everything in medicine from a Tylenol to a transplant has a risk and benefit. If you are 105 years old and had a heart attack last week, you're not going to be eligible. If you're 40 and otherwise healthy, you're eligible and everywhere in between is an evaluation of risks and benefits.

How would you describe the standard of care for patients with multiple myeloma?

In general, the standard of care is to attempt to get people onto three drugs. The three drugs usually mean a steroid, and then either an immunomodulatory drug, a proteasome inhibitor or a monoclonal antibody, and using those different combinations to come up with two or three-drug combinations, and actually in some cases four-drug combinations.

The general discussion of which one makes sense is we generally try to put some on a three-drug combination and the two most common ones now VRd (Velcade, Revlimid, and dexamethasone) is really a very big standard approach. There's some really wonderful, emerging data from the MAIA study, looking at taking Revlimid and dexamethasone and adding Darzalex (daratumumab) as a three-drug regimen for people who are not going on to transplant and some of that data looks amazing.

But for the most part, the precision that we use has to do not so much with the tumor but with the patient. Meaning for some diseases, the precision in the upfront setting is we look at a genetic marker and we target that. But for myeloma our upfront choice of therapy is saying, what are your comorbidities? What are your risks? For someone who has neuropathy, we may avoid Velcade. Someone has heart issues, we may avoid carfilzomib (Kyprolis) and if someone has difficult coming back and forth for long infusions, we may avoid Darzalex. So, most of the precision that we use is custom tailoring it not necessarily to the disease upfront, although that's part of it, but also to the patient.

What is the role of stem cell transplantation in treating patients with multiple myeloma?

The role of transplant is constantly evolving in myeloma. A generation ago, when we didn't have very good drugs, transplant was clearly the best thing to do because we didn't have good medicines. Transplant was the only way to get deep and durable remissions. Nowadays that we have such better therapies and even better ones along the way, it's being called into question about how much do we still need transplant. And it's a case by case basis, some people still clearly benefit from transplant.

It's an important discussion to have with your provider. But the risks have been well established for many years and we know how to manage them very well. Although there are risks for it, they're generally consolidated into a couple weeks to a couple of months, as opposed to being on long term treatment that can have ongoing risk of side effects. So, yes, they may be higher, but it's usually for a self-contained amount of time.

It's still a very important tool in our armamentarium to treat patients. Now, that being said, the majority of patients in the United States do not receive autologous transplant, so only about 30% and part of the reason has to do with the age of patients. The average age of a myeloma patient in the U.S. is 69, and many people in their 70s and 80s have other medical problems that make them not eligible for transplant.

There are some socioeconomic reasons, as well as referral patterns and access to care. I live in New York City, you can throw a rock and hit a transplant center, but there are parts of the country where the closest transplant center is hours and hours and hours away. And if you are older, sick or don't have easy transportation, it may be more difficult. So, many people do not receive transplant. However, many people nowadays may not even need it because our drugs have gotten so much better.

See more here:
Understanding the Key Aspects of a Multiple Myeloma Diagnosis - Curetoday.com

Read More...

Alzheimer ‘Tau’ Protein Far Surpasses Amyloid in Predicting Toll on Brain Tissue – UCSF News Services

January 3rd, 2020 8:41 am

Brain imaging of pathological tau-protein tangles reliably predicts the location of future brain atrophy in Alzheimers patients a year or more in advance, according to a new study by scientists at the UC San Francisco Memory and Aging Center. In contrast, the location of amyloid plaques, which have been the focus of Alzheimers research and drug development for decades, was found to be of little utility in predicting how damage would unfold as the disease progressed.

The results, published Jan. 1, 2020, in Science Translational Medicine, support researchers growing recognition that tau drives brain degeneration in Alzheimers disease more directly than amyloid protein, and at the same time demonstrates the potential of recently developed tau-based PET (positron emission tomography) brain imaging technology to accelerate Alzheimers clinical trials and improve individualized patient care.

The match between the spread of tau and what happened to the brain in the following year was really striking, said neurologist Gil Rabinovici, MD, the Edward Fein and Pearl Landrith Distinguished Professor in Memory and Aging and leader of the PET imaging program at the UCSF Memory and Aging Center. Tau PET imaging predicted not only how much atrophy we would see, but also where it would happen. These predictions were much more powerful than anything weve been able to do with other imaging tools, and add to evidence that tau is a major driver of the disease.

Alzheimers researchers have long debated the relative importance of amyloid plaques and tau tangles two kinds of misfolded protein clusters seen in postmortem studies of patients brains, both first identified by Alois Alzheimer in the early 20th century. For decades, the amyloid camp has dominated, leading to multiple high-profile efforts to slow Alzheimers with amyloid-targeting drugs, all with disappointing or mixed results.

Many researchers are now taking a second look at tau protein, once dismissed as simply a tombstone marking dying cells, and investigating whether tau may in fact be an important biological driver of the disease. In contrast to amyloid, which accumulates widely across the brain, sometimes even in people with no symptoms, autopsies of Alzheimers patients have revealed that tau is concentrated precisely where brain atrophy is most severe, and in locations that help explain differences in patients symptoms (in language-related areas vs. memory-related regions, for example).

No one doubts that amyloid plays a role in Alzheimers disease, but more and more tau findings are beginning to shift how people think about what is actually driving the disease, explained Renaud La Joie, PhD, a postdoctoral researcher in Rabinovicis In Vivo Molecular Neuroimaging Lab, and lead author of the new study. Still, just looking at postmortem brain tissue, it has been hard to prove that tau tangles cause brain degeneration and not the other way around. One of our groups key goals has been to develop non-invasive brain imaging tools that would let us see whether the location of tau buildup early in the disease predicts later brain degeneration.

Despite early misgivings that tau might be impossible to measure in the living brain, scientists recently developed an injectable molecule called flortaucipir currently under review by the FDA which binds to misfolded tau in the brain and emits a mild radioactive signal that can be picked up by PET scans.

Rabinovici and collaborator William Jagust, MD, of UC Berkeley and Lawrence Berkeley National Laboratory, have been among the first to adopt tau PET imaging to study the distribution of tau tangles in the normally aging brain and in a smaller cross-sectional study of Alzheimers patients. Their new study represents the first attempt to test whether tau levels in Alzheimers patients can predict future brain degeneration.

La Joie recruited 32 participants with early clinical stage Alzheimers disease through the UCSF Memory and Aging Center, all of whom received PET scans using two different tracers to measure levels of amyloid protein and tau protein in their brains. The participants also received MRI scans to measure their brains structural integrity, both at the start of the study, and again in follow-up visits one to two years later.

The researchers found that overall tau levels in participants brains at the start of the study predicted how much degeneration would occur by the time of their follow up visit (on average 15 months later). Moreover, local patterns of tau buildup predicted subsequent atrophy in the same locations with more than 40 percent accuracy. In contrast, baseline amyloid-PET scans correctly predicted only 3 percent of future brain degeneration.

Seeing that tau buildup predicts where degeneration will occur supports our hypothesis that tau is a key driver of neurodegeneration in Alzheimers disease, La Joie said.

Notably, PET scans revealed that younger study participants had higher overall levels of tau in their brains, as well as a stronger link between baseline tau and subsequent brain atrophy, compared to older participants. This suggests that other factors likely other abnormal proteins or vascular injuries may play a larger role in late-onset Alzheimers, the researchers say.

The results add to hopes that tau-targeting drugs currently under study at the UCSF Memory and Aging Center and elsewhere may provide clinical benefits to patients by blocking this key driver of neurodegeneration in the disease. At the same time, the ability to use tau PET to predict later brain degeneration could enable more personalized dementia care and speed ongoing clinical trials, the authors say.

One of the first things people want to know when they hear a diagnosis of Alzheimers disease is simply what the future holds for themselves or their loved ones. Will it be a long fading of memory, or a quick decline into dementia? How long will the patient be able to live independently? Will they lose the ability to speak or get around on their own? These are questions we cant currently answer, except in the most general terms, Rabinovici said. Now, for the first time, this tool could let us give patients a sense of what to expect by revealing the biological process underlying their disease.

Rabinovici and his team also anticipate that the ability to predict future brain atrophy based on tau PET imaging will allow Alzheimers clinical trials to quickly assess whether an experimental treatment can alter the specific trajectory predicted for an individual patient, which is currently impossible due to the wide variability in how the disease progresses from individual to individual. Such insights could make it possible to adjust dosage or switch to a different experimental compound if the first treatment is not affecting tau levels or altering a patients predicted trajectory of brain atrophy.

Tau PET could be an extremely valuable precision medicine tool for future clinical trials, Rabinovici said. The ability to sensitively track tau accumulation in living patients would for the first time let clinical researchers seek out treatments that can slow down or even prevent the specific pattern of brain atrophy predicted for each patient.

Authors: La Joie is corresponding author on the study; Rabinovici is senior author. Additional authors on the study are Adrienne V. Visani, Jesse A. Brown, Viktoriya Bourakova, Jungho Cha, Kiran Chaudhary, Lauren Edwards, Leonardo Iaccarino, Orit Lesman-Segev, Zachary Miller, David C. Perry, Julie Pham, Julio C. Rojas, Howard J. Rosen, William W. Seeley, Richard M. Tsai, and Bruce L. Miller, all of UCSF; Suzanne L. Baker, Mustafa Janabi, and James P. ONeil, of Lawrence Berkeley National Laboratory (LBNL); and Jagust, of LBNL and UC Berkeley.

Funding: The study was supported by the Alzheimers Association (AARF-16-443577), the National Institute on Aging (NIA) of the US National Institutes of Health (R01-AG045611, P50-AG023501, P01-AG19724), the Tau Consortium, and an Alzheimers Disease Research Center of California grant (04-33516) from the California Department of Health Services.

Disclosures: Rabinovici receives research support from Avid Radiopharmaceuticals, GE Healthcare, and Life Molecular Imaging, and has received consulting fees or speaking honoraria from Axon Neurosciences, Roche, Eisai, Genentech, Merck. La Joie reports no conflicts of interest. See study online for a full list of conflict of interest disclosures.

The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.UCSF Health, whichserves as UCSFs primary academic medical center, includestop-ranked specialty hospitalsandother clinical programs,and has affiliations throughout the Bay Area.

See the rest here:
Alzheimer 'Tau' Protein Far Surpasses Amyloid in Predicting Toll on Brain Tissue - UCSF News Services

Read More...

HIT-related developments in APAC A 2019 Overview – Healthcare IT News

January 3rd, 2020 8:41 am

National level developments

Malaysia Health Minister Datuk Seri Dr Dzulkefly Ahmad has said back in November 2018 that the Ministry of Health is committed to ensuring that the electronic medical record system (EMR) can be realised within three years at 145 hospitals nationwide. He estimated that it would cost up to RM1.5B to implement an EMR system for the 145 hospitals nationwide in Malaysia over the next five years, HealthcareIT News reported in July 2019. While there has been quite a lot of buzz about the nation-wide EMR implementation in the country, there seems to be a lack of concrete developments in the discussion and execution of the said EMR system, something that we hope to see more of in 2020.

Vietnam, on the other hand, has gone ahead and deployed their nationwide EHR in July last year, with 24 provinces implementing EHRs. Australias My Health Record (MHR) has a participation rate of 90% and the Australian Digital Health Agency (ADHA), which is in charge of MHR, has been working with software vendors to improve the functionality of the MHR.

At the HIMSS AsiaPac19 conference in October 2019, the HIMSS Thailand National Digital Healthcare Workforce Development Initiative (WDI) was officially launched. This Initiative sees the development of a three-year work plan to address the demand of patients for digital healthcare services in light of the Thailand 4.0 digitization journey, as well as healthcare tourism being one of the key economy drivers.

As part of the HIMSS Thailand National Digital Healthcare WDI, HIMSS also announced its intention to enter into a memorandum of understanding (MoU) with True Digital Group, a subsidiary of True Corporation, a leading communications conglomerate in Thailand, to create a HIMSS Digital Health Centre @ True Digital Park, which is slated to be launched in early 2020.

Singapores Deputy Prime Minister and Minister of Finance Heng Swee Kiat announced in November 2019 a national Artificial Intelligence (AI) strategy to transform Singapores economy and improve the lives of citizens. In terms of healthcare, the emphasis of the national AI strategy will be on chronic disease management and prevention. This includes the deployment of the Singapore Eye Lesion Analyzer, Selena+, a system which analyzes retinal photographs across the nation for diabetes screening by 2022.

Much ado about AI and its applications in healthcare

During the panel discussion on the current and future developments of AI at the HIMSS Singapore eHealth & Health 2.0 Summit in April 2019, Dr Ngiam Kee Yuan, GCTO, NUHS, observed that AI technologies in healthcare are slightly overhyped but in terms of real adoption, there needs to be factors like a really mature EHR system, good data streams, finding ways to deploy these AI technologies and training doctors to buy in into using these technologies. Simply put, good AI technology implementation in healthcare cannot just happen in a vacuum.

AI (in healthcare) needs to be human-centric and this sentiment is agreed upon by panelists at the Innofest Unbound conference in Singapore. A lot of radiologists are already using Computer Aided Diagnosis (CAD) for mammography and it has been happening for some time. So the idea is for us as a tech startup to pursue what we call human-centric AI. We try to make AI as explainable as possible and we always want humans to be involved in the whole process, said Dr Reid Lim, founder of MEDGIC, a startup which utilizes AI to detect skin conditions.

Cybersecurity risks still prevalent

Despite being more advanced than its neighbors in APAC, Singapore was hit by another healthcare cybersecurity incident in February 2019, which saw the leak of confidential information regarding 14,200 individuals diagnosed with HIV. Ransomware attacks hit hospitals and health services in Victoria, Australia in October 2019 and some facilities have had to revert to manual systems to maintain services.

Richard Staynings, Chief Security Strategist, Cylera said in an HealthcareIT News interview that healthcare compliance does not equal to security and the industry needs to adopt a risk-based approach to security based upon assets rather than controls.

2020 predictions?

The introduction of more user-friendly, less costly and accurate Internet of Medical Things (IoMT) devices, combined and complemented with advanced analytics, will take healthcare to the next level of value-driven care and personalized medicine, said Benedict Tan, Group Chief Digital Strategy Officer, SingHealth and Chairperson, Organizing Committee, HIMSS AsiaPac 20 Conference.

Follow this link:
HIT-related developments in APAC A 2019 Overview - Healthcare IT News

Read More...

Israeli scientists shed new light on how the brain functions – The Jerusalem Post

January 3rd, 2020 8:41 am

How does the brain work? What is the connection between its structure and its functioning? A team of Israeli scientists from the Technion Institute of Technology, in cooperation with colleagues from the US and France, has managed to demonstrate the significance of personalized brain models, which could have a meaningful impact in the field of personalized medicine.In an academic article published Thursday in PNAS, the official journal of the National Academy of Sciences of the United States, the group demonstrated that the individual map of structural neural connections, which are the physical links between regions, predicts the individual functional connectivity patterns, namely, how neural activity is spreading in the brain.As explained in a statement, the researchers took advantage of mice studies to "systematically investigate the informative content of different structural features in explaining the emergence of the functional ones."They employed structural magnetic resonance imaging (MRI) to scan mice's brains, then built a virtual model of their brain and tried to simulate their functional organization based on the structural connectivity, finally comparing it to the results of functional MRI on the same mice.With this study, the scientists were able to demonstrate that individual variations define a specific structural fingerprint with a direct impact upon the functional organization ofindividual brains. This finding will potentially support future clinical trials focusing on personalized treatments in brain disorders such as epilepsy, depression and Alzheimers disease, in which the virtual brain may predict treatment outcome in individual patients.The study was conducted by Professor Itamar Kahn, director of the Brain Systems Organization in Health and Disease Lab at Technion. Graduate students Eyal Bergmann and Francesca Melozzi were lead co-authors. Kahn's work focuses on investigating brain function and behavior in health and disease. As explained in the American Technion Society's website, his research has applications for neurodegenerative diseases such as Alzheimer's and Parkinson's and neurodevelopmental disorders including autism and attention deficit hyperactivity disorder.

View original post here:
Israeli scientists shed new light on how the brain functions - The Jerusalem Post

Read More...

Why Aurora Cannabis, Canopy Growth, and Other Top Canadian Marijuana Stocks Soared Today – Nasdaq

January 3rd, 2020 8:41 am

What happened

Several top Canadian marijuana stocks soared by double-digit percentages on Tuesday. Shares of Aurora Cannabis (NYSE: ACB) were up by 12.3% as of 3:08 p.m. EST. Canopy Growth (NYSE: CGC) stock was jumping 12.1%. Tilray's (NASDAQ: TLRY) gain for the day was in the same ballpark, with shares up 12.5%. Aphria (NYSE: APHA) lagged behind slightly, with the stock rising 10.6%.

Two of the biggest winners, though, were Cronos Group (NASDAQ: CRON) and Sundial Growers (NASDAQ: SNDL), with shares vaulting 16.8% and 22.6% higher, respectively.

What lit a fire beneath these Canadian marijuana stocks on the last day of 2019? There wasn't any major news today. Probably the biggest factor behind today's spike is that the Cannabis 2.0 market for cannabis derivative products is picking up steam. Most of the stocks that jumped also have double-digit short percentages of shares outstanding, so any upward movement can result in short-sellers closing out their positions, contributing to even greater increases in share prices.

Image source: Getty Images.

All of the big marijuana stocks with big moves today have taken a shellacking in 2019, with the exception of Aphria, which fell only slightly during the year. The lack of an adequate retail infrastructure, particularly in Ontario, has presented a major obstacle for Canadian cannabis producers. However, the year is ending on a positive note; Ontario is taking steps to open more retail stores at the same time the Cannabis 2.0 market is shifting into gear.

There's a good reason for investors to be optimistic about the potential for these stocks in the Cannabis 2.0 market. Professional services organization Ernst & Young projects the market could reach close to 6 billion Canadian dollars by 2025.

It's still very early, though. Today's jump stems from anticipation and hopes, instead of hard sales numbers. Still, many investors could be justified in thinking that the 2019 sell-off for Canadian pot stocks could have been overdone, in light of the improving environment that should be on the way in 2020.

Watch for reports of how well sales in the Cannabis 2.0 market are going early in the new year. Aphria will be the first major Canadian cannabis producer to announce earnings results, on Jan. 14, 2020. Although those results are for the quarter ending in November and won't include any Cannabis 2.0 sales, the company's management could provide some insight into how the launch of its new products is going.

Here's The Marijuana Stock You've Been Waiting ForA little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake it is coming.

Cannabis legalization is sweeping over North America 11 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.

And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.

Because a game-changing deal just went down between the Ontario government and this powerhouse company...and you need to hear this story today if you have even considered investing in pot stocks.

Simply click here to get the full story now.

Learn more

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Link:
Why Aurora Cannabis, Canopy Growth, and Other Top Canadian Marijuana Stocks Soared Today - Nasdaq

Read More...

In 2020, AI to enable acceleration from automation to autonomy, say experts – Robot Report

January 3rd, 2020 8:41 am

In 2020, AI could empower robotics with tools such as this Brain Bulder workspace. Source: Neurala

For the past decade, robotics has been one of the most interesting areas for developers, industry analysts, and startups to focus on. From emerging technologies and new applications to ongoing challenges, both innovators and entrepreneurs will have a lot to watch in 2020.

The Robot Report spoke with the following executives at robotics and artificial intelligence companies about their observations of 2019s trends, as well as their expectations for the new year:

Which technologies do you expect to mature the most in 2020, such as the Industrial Internet of Things (IIoT), edge computing, 5G wireless networks, or autonomous vehicles?

Visti: In 2020, Industry 4.0 will become more of a reality than a vision. Smart machines keep getting smarter as they get access to more data, and they keep getting better at connecting to other machines and systems, and therefore they become truly useful for manufacturers.

Thomas Visti, Mobile Industrial Robots

While many companies have been hesitant and seen Industry 4.0 as merely a buzzword, were starting to see connected supply chains where MES [manufacturing execution systems], robots, and picking systems are connected.

We also see the connectivity between robots and ERP [enterprise resource planning] systems within production environments.

The entire process from ordering to producing and then transporting goods can now be fully automated. Industry 4.0 is still evolving, and it will not reach its full potential in 2020, but we will see more companies adopting the enabling technologies. This will also influence the workforce, as we will see the same companies wanting to upskill their current workforce and recruit new employees with Industry 4.0 skills.

Versace: Well see more demand for AI that can be trained, deployed, and refined at the edge. 2019 has shown us that many organizations, robotics companies included, are saying No to giving up their data and having to ping the cloud.

I believe that in 2020, AI will need to live and learn at the edge, so that processing occurs where the data is being generated. As a result, robotics companies will see reduced latency problems while mitigating privacy issues and massive cloud fees for manufacturers.

Sudhir Jha, Brighterion

Jha:Enterprises will transition into deploying complex AI models in production at scale. So far, most AI applications are experiments but not in production, simple recommendation/prediction/regression models, or applied to smaller problems.

In 2020, we will see more enterprises getting bolder with their AI ambitions and requiring their vendors to support large deployments.

There will be be an acceleration from automation to autonomy, and AI will play the most crucial role in this. Also, robotics will move further from industrial arena to consumer arena, where they will act as personal coaches, instructors for children, conversational buddies for elders, and guides for the disabled.

Which market or application represents the biggest area of growth potential in 2020?

Visti: We expect to see an increase in the use of robotics in all our existing markets such as automotive, electronics, FMCG [fast-moving consumer goods], pharmaceuticals, and more.

There is still a huge focus on optimization, and with the lack of qualified workers, the need for automation across industries has never been higher.

We expect big growth in the use of AMRs by the 3PL [third-party logistics] segment, which has not been an early adopter of AMRs. In fact, our recent survey showed that only around 50% of 3PLs are currently considering automating internal logistics with AMRs. We expect to see this figure increase significantly in 2020 and the years ahead.

The hospital sector is also looking to automate internal transportation worldwide. For MiR, we have many customers within this segment in Scandinavia and China, but we expect it to grow even more.

Jha: Verticals like healthcare will see expanded AI-based applications, not only in the areas of diagnosis and personalized medicine, but also on the operational side like customer service, payment processing, and FWA (fraud, waste, and abuse).

How will trade conflicts or the slowdown in automotive manufacturing affect robotics in 2020?

Visti: While the automotive manufacturing market may have slowed, the latest statistics from the Robotic Industries Association actually shows what looks like an uptick in ordering of industrial robots by automotive OEMs, up 47% for 2019 over 2018.

Were also experiencing increased growth in that market and overall, with companies like Toyota and Ford purchasing fleets of our AMRs.

We expect this is due to these manufacturers realizing how automation can help fill difficult-to-fill jobs; increase overall productivity; and enable humans to focus on higher-skilled, higher-quality, and higher-paid tasks. These are all benefits that can lead to growth and new job opportunities, which could help turn the automotive industry back around.

Versace: We will always be faced with some degree of socioeconomic uncertainty around the world. In terms of manufacturing, possible decoupling of Chinese and Western economies may actually bolster manufacturing in the U.S. and make it less reliant on overseas production in the long run. This may indirectly boost robotic deployments in the U.S. and Europe.

But at Neurala, were focused on what we can control, which is first and foremost to provide robotics and other companies with an AI platform that they can apply to solve real-world challenges. Our Brain Builder platform is helping organizations accelerate the process of building, deploying, and analyzing AI so they can focus on improving visual inspections.

Related content: Industry experts provide more robotics predictions for 2020

What challenges and opportunities do you expect for AI in 2020?

Jha: As AI-based solutions become more mainstream across industries, we need to carve out a handful domain where our technology provides sustainable differentiation and allows us to be a leader.

We have focused on risk and compliance areas in financial services and are looking to diversify in other verticals. Also our strength in building mission-critical applications in highly regulated industries will serve us well to ensure data privacy and ethical use of AI which is a growing trend globally.

Max Versace, Neurala

Versace: Im thinking of 2020 as the Year of Productization and the Customer.

At Neurala, well continue to work with customers so that they can independently build and deploy custom AI applications for the real world.

Furthermore, AI products such as Brain Builder will enable customers with little or no expertise in AI to build an end-to-end application from scratch, on their proprietary data. This means that enterprises will no longer be restricted by their size or resources when it comes to implementing AI as a part of their business strategies.

Read more from the original source:
In 2020, AI to enable acceleration from automation to autonomy, say experts - Robot Report

Read More...

Precision Medicine Market to Restrict Revenue Growth During the Forecast Period 2025 Bulletin Line – Bulletin Line

January 3rd, 2020 8:41 am

According to the latest study conducted byMarket Growth Analysisthe global market for precision medicine is anticipate grow manifold, reflecting a robust CAGR of over XX% during 2018 to 2025.

Rapid augmentation of the medicine industry across the globe will certainly benefit the global market for precision medicine. In addition, factors such as growing infrastructural development, higher investments, streamlined drug approval systems along with companion diagnostics are expected to favor the overall market growth during the assessment period. Cost-effective DNA profiling and increasing prevalence of carcinogenic diseases worldwide are additional factors that are projected to propel the market growth. Moreover, apt storage of genome data is of great significance to the global market for precision medicine as demand for data medicare is on the rise. However, acute data storage capacity, data privacy breach and discrepancies in funding systems and hefty price tag of personalized drugs may deter the market growth in the near future.

Request a Report Sample with Toc and figures to click here: http://marketgrowthanalysis.com/reports/sample/436

The global market for precision medicine has been categorized into various parent segments that are further segmented into smaller sub-divisions.

On the basis of technology, next-gen sequencing, bioinformatics and drug discovery technology are expected to be the technologies highlighting the expanding the market width in forthcoming years. Based on applications, the oncology segment is expected to witness an overwhelming growth and is estimated to reach US$ XX Billion over 2025, reflecting a staggering XX% CAGR. This is primarily owing to increasing prevalence of tumor-related disease amongst the global geriatric population. On the other hand, increasing cases of arthritis will favor the growth of immunology segment, which is expected to surpass US$ XX Million in revenues by 2025 end.

Vendor News

Key players operating in the global market for precision medicine include Eli Lilly And Company, Novartis AG, AstraZeneca and Laboratory Corporation of America Holdings. Most of the companies are implementing market strategies involving mergers, tie-ups and acquisitions. Increasing collaboration between healthcare and IT is expected to deliver fruitful gains to the market, expanding the overall business canvas for the stakeholders in the upcoming years.

Request for enquiry on This Report at: http://marketgrowthanalysis.com/reports/enquiry/436

The popularity of precision medicine has grown significantly across various parts of the world, hence on the basis of region, the markets for precision medicine in Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa (MEA) is set to achieve new figures of growth over the next eight years. Precisely, the market in North America is expected to present new lucrative opportunities, occupying over XX% share of the market during the forecast period. In addition, the region is estimated to surpass a market valuation of over US$ XX Million by the end of 2025.

The US and Canada will be the heavyweights of the global market owing to the existence of well-established medical industries in both the countries. In Europe, the market is expected to witness a steady growth and will increase its revenues charts close to US$ XX Million, riding on a healthy CAGR of over XX% during the assessment period. This is largely due to the increasing demand for precision medicines in countries such as France, UK, Italy and Germany. The Asia Pacific region is another region which is considered to be full of business potentials. The region is projected to increase at over XX% CAGR to reach approximately US$ XX Million by 2025 end. The market in APAC will be heavily dominated by Japan, while, India and China will compete for the second spot. Likewise, the in Latin America the market is expected to surge at a pace in terms of revenue over 2025. However, MEA will witness a sluggish growth of the market which is attributed to the lack of initiatives for conductive extensive research and development activities.

Browse more detail information about this report visit at: http://marketgrowthanalysis.com/precision-medicine-market

See more here:
Precision Medicine Market to Restrict Revenue Growth During the Forecast Period 2025 Bulletin Line - Bulletin Line

Read More...

Gene Therapies Make it to Clinical Trials – Discover Magazine

January 1st, 2020 7:45 pm

After years of ethical debates and breakthroughs in the lab, CRISPR has finally made its way to clinical trials. Researchers are now looking at whether the DNA-editing tool, as well as more conventional gene therapies, can effectively treat a wide array of heritable disorders and even cancers.

Theres been a convergence of the science getting better, the manufacturing getting much better, and money being available for these kinds of studies, says Cynthia Dunbar, a senior investigator at the National Heart, Lung, and Blood Institute. Its truly come of age.

CRISPR formally known as CRISPR-Cas9 has been touted as an improvement over conventional gene therapy because of its potential precision. CRISPR (clustered regularly interspaced short palindromic repeats) is a genetic code that, contained in a strand of RNA and paired with the enzyme Cas9, acts like molecular scissors that can target and snip out specific genes. Add a template for a healthy gene, and CRISPRs cut can allow the cell to replace a defective gene with a healthy one.

In April, scientists at the University of Pennsylvania announced they had begun using CRISPR for cancer treatments. The first two patients one with multiple myeloma, the other with sarcoma had cells from their immune systems removed. Researchers used CRISPR to genetically edit the cells in the lab, and then returned them back into their bodies.

On the other side of the country, Mark Walters, a blood and bone marrow transplant specialist at the University of California, San Francisco, Benioff Childrens Hospital in Oakland, is gearing up for trials that will use CRISPR to repair the defective gene that causes sickle cell disease. With CRISPR, once youve made that type of correction, [that cell] is 100 percent healthy, says Walters.

Another team is tackling the same disease using a type of hemoglobin, a protein in red blood cells, thats normally made only in fetuses and newborn babies. Researchers found that some adults continue to produce these proteins throughout their lives, and when those adults also have sickle cell disease, their symptoms are mild. So the international team used CRISPR to disable the gene that interferes with production of this hemoglobin, resuming its production and protecting the adult patients against sickle cell disease.

Several other CRISPR studies are in the works to treat a range of inherited disorders, including hemophilia and SCID-X1 (also known as X-linked severe combined immunodeficiency, the so-called bubble boy disease in which babies are born without a functioning immune system).

At St. Jude Childrens Research Hospital, a gene therapy trial cured Gael Jesus Pino Alva (pictured with his mother, Giannina) of SCID-X1, the bubble boy disease. (Credit: St. Jude Children's Research Hospital/Peter Barta)

The past year also saw success in a handful of experiments on conventional gene therapy. Instead of using CRISPR to repair disease-causing genes, these treatments use hollowed-out viruses to ferry healthy versions of genes into cells. Millions of these altered cells are released into the bloodstream or bone marrow in hopes that enough will land in the right places. But because scientists cant predict where the circulating genes may end up, this shotgun approach has had unintended, sometimes fatal, consequences including, in an earlier study, inadvertently activating leukemia-causing genes in patients treated for SCID-X1.

But in 2019, researchers learned that using a different type of virus one related to HIV to transport the genes may prevent these side effects. In an April study, researchers at St. Jude Childrens Research Hospital in Memphis, Tennessee, and UCSF Benioff Childrens Hospital in Oakland collected bone marrow from eight newborns with SCID-X1. They loaded corrective genes into the disabled HIV-related virus, which carried them into the patients bone marrow stem cells. The infants also received low doses of busulfan, a chemotherapy that gave the doctored stem cells room to grow. So far, we havent seen anything worrisome, says Ewelina Mamcarz, a pediatric oncologist at St. Jude who led the research team. The study recently added its 12th patient.

Gene therapy does have its momentum [back], says Mamcarz, reflecting on the fields setback after the earlier studys leukemia side effects. Theres so much that still needs to be done, and so many questions, she says. [But] this is how medicine evolves. We always want to be better than we were a week ago.

In the future, the hope is that gene therapy technologies will move beyond mending simple genetic mistakes and be used to combat big killers like diabetes or heart disease. [Those diseases are] more challenging, but a lot of them would benefit from knocking out a bad gene, says Dunbar.

For now, though, researchers are optimistic about the progress thats already been made. All of this has been very encouraging, says Dunbar. [And] for sickle cell in the U.S. and hemophilia in the developed world, these diseases may soon be solved.

[This story originally appeared in print as "Gene Therapy Gets Clinical."]

Originally posted here:
Gene Therapies Make it to Clinical Trials - Discover Magazine

Read More...

Deficiency of TRPM2 leads to embryonic neurogenesis defects in hyperthermia – Science Advances

January 1st, 2020 7:45 pm

INTRODUCTION

The cerebral cortex is the most evolved and complicated structure in the mammalian brain and has many physiological functions, such as attention, cognition, learning, and memory. The functions rely on the detailed cortex structure, which includes a six-layered architecture formed by migrating neurons in an inside-out pattern (1). These plentiful neurons are generated from various neural progenitor cells (NPCs). The primary progenitor cells are radial glial (RG) cells, which are mainly responsible for self-renewal and result in the expansion of the cortex, the differentiation of neurons, and the production of postmitotic neurons (2). The process of neuronal production, also known as neurogenesis, plays crucial roles in cerebral development and can affect the function of the neocortex. Generally, each process in neurogenesis, including self-renewal, differentiation, and the maturation of neurons, is strictly regulated, and any disturbance leads to severe disorders (3). The entire process is regulated by numerous extracellular and intracellular signals and factors. Any stress or unusual stimulus may lead to abnormalities in brain function.

During pregnancy, various stimuli can lead to abnormal neural development (4, 5). Among them, heat stress is an important stimulus for both the mother and fetus during pregnancy, and maternal thermal homeostasis is critical for fetal survival and ontogenesis. For example, maternal fever during the gestation period is associated with congenital heart defects and neural tube defects (6, 7). However, it is largely unknown whether heat stress, such as hyperthermia, disturbs neurogenesis and cortical development.

A series of thermally activated ion channels has been reported to detect the entire thermal range (8, 9). Among them, transient receptor potential channel M2 (TRPM2) is a plasma membrane calcium-permeable cation channel and is a unique member of the TRP family that is sensitive to various signals. Recently, studies have reported that TRPM2 can be activated by heat and that the deletion of TRPM2 in mice results in a remarkable deficit in their perception of nonpainful warm stimuli in the range of 33 to 38C (10). TRPM2 has been implicated in several neurodevelopmental/neurological disorders including bipolar disorder, neuropathic pain, and Parkinsons disease (11). In addition, TRPM2 has been shown to participate in various biological processes, including insulin secretion, H2O2-induced cell apoptosis, and brain damage following ischemic insults in adult and neonatal mice (1214). Therefore, it is crucial to investigate the precise functions and molecular mechanisms of the hyperthermia-related protein TRPM2 and characterize the proteins role in the regulation of brain development during heat stress and maternal hyperthermia.

Several pieces of evidence have demonstrated that canonical Wnt signaling, including -catenin, which acts as a core downstream effector, determines the transition from neuronal proliferation to differentiation during cortical neurogenesis. In the early stages of neurogenesis, the overexpression of -catenin in NPCs promotes their proliferation, whereas a deficiency in -catenin in NPCs facilitates neurogenesis (15). The precise signal transductions that modulate neurogenesis are unclear and need further elucidation. The transcription factor SP5 (specificity protein 5) is a member of the SP transcription factor family (16), and previous studies have shown that SP5 plays a crucial role in governing mouse embryonic stem cell pluripotency (17) and neural crest specification (18). During vertebrate development, SP5 acts downstream of Wnt/-catenin signaling in neuroectoderm patterning (19). In addition, the hypermethylation of SP5 has been implicated in schizophrenia, a neuropsychiatric disorder associated with the dysregulation of neural stem cell (NSC) proliferation and differentiation (20, 21). However, the role of SP5 in hyperthermia during neurogenesis has never been reported.

Here, we demonstrate that the thermo-sensor protein TRPM2 is enriched in the embryonic cerebral cortex and that its expression gradually increases during heat stress. We also show that TRPM2-deficient mice exposed to heat show reduced NSC proliferation and a premature shift in RG differentiation. Mechanistically, this study identifies an important role of TRPM2 in modulating SP5 expression by inhibiting the phosphorylation of -catenin in sustaining neural progenitor self-renewal during heat stress. In addition, the heat-induced proliferation defects caused by TRPM2 knockdown or knockout can be partially rescued by the overexpression of SP5. Collectively, these findings reveal that the heat sensor protein TRPM2 has a previously unidentified role in modulating cortical neurogenesis during hyperthermia conditions. These findings provide previously unknown insights to further elucidate neurological disorders associated with heat stress and reveal previously unidentified strategies for treatment.

To determine the effect of heat stress on the developing cortex, we performed stress experiments in which pregnant mice were placed in a thermostatic biochemical incubator (fig. S1A) set to 38C for 2 hours from embryonic day 13.5 (E13.5) to E15.5; the control group was kept at room temperature. After heat stress, E15.5 brain slices were stained with an antibody against mitotic index PH3. Compared with that in the control group, the number of PH3-positive cells residing at both the apical and basal positions was notably augmented, indicating that heat stress promoted mitotic activity (Fig. 1, A to C). Consistently, double staining for bromodeoxyuridine (BrdU) with PAX6 (one type of neural progenitor marker) (Fig. 1, D and E) and TBR2 (an intermediate progenitor marker) (Fig. 1, F and G) revealed that the number of cells in the proliferative state was increased in hyperthermia. Collectively, these results indicate that heat stress promotes neural progenitor self-renewal. In a second group of pregnant mice, similar heat stress was induced at E13.5 to E16.5; then, in utero electroporation (IUE) was performed to analyze embryonic brain development. When embryos were electroporated with a green fluorescent protein (GFP)encoding plasmid, which was used as a control plasmid on E13.5 and collected on E16.5, the hyperthermia group showed an abnormal distribution, which manifested as an increase in the number of cells in the ventricular zone/subventricular zone (VZ/SVZ) and a reduction in the number of GFP-positive cells in the cortical plate (CP) compared with those in the room temperature group (Fig. 1, H and I). In our research, the control mice were maintained in the vivarium at room temperature. We also conducted IUE experiments when mice were maintained in an incubator or in the vivarium at room temperature and found that the stress experienced by the mother due to moving to a new environment did not play a role in the observed phenotypes (fig. S1, B and C). Together, these results demonstrate that heat stress may disturb neurogenesis during embryonic brain development.

(A to C) E15.5 brain sections from the room temperature and hyperthermia groups were immunolabeled with the mitotic marker PH3 and 4,6-diamidino-2-phenylindole (DAPI). The graphs show the number of PH3+cells per 100 m2 at the apical and basal positions (n = 6). Scale bar, 20 m. (D to G) Mice underwent 2 hours of BrdU pulse labeling and were euthanized at E15.5. Brain slices were then double stained with antibodies against BrdU/PAX6 and BrdU/TBR2. The graphs show the populations of BrdU+PAX6+ and BrdU+TBR2+ cells relative to the total population of BrdU+ cells (n = 6). Scale bars, 20 m. (H and I) Thermal stimuli lead to the abnormal distribution of GFP-positive cells in the developing neocortex. An electroporation experiment was conducted at E13.5, and embryonic brains were collected on E16.5. The percentage of GFP-positive cells in each region is displayed in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. IZ, intermediate zone. (J) Reverse transcription polymerase chain reaction (RT-PCR) results showing the relative mRNA levels of members of the TRP family in the heat stress experiment (n = 3). n.s., not significant. (K) TRPM2 is abundantly enriched in NESTIN-positive NSCs in the embryonic cerebral cortex. E13.5 and E15.5 brain slices were immunostained with anti-NESTIN and anti-TRPM2 antibodies (VZ/SVZ) (n = 5). Scale bars, 20 m. (L) TRPM2 is expressed and colocalized with SOX2 and NESTIN in primary NSCs. The cells were collected from the cerebral cortex of E12.5 mouse brains and maintained in proliferative medium for 24 hours (n = 4). Scale bars, 20 m. (M and N) TRPM2 expression increases at warm temperatures in the E15.5 cerebral cortex. E15.5 brain sections were stained with an antibody against TRPM2. The graph shows the relative expression intensities of TRPM2 (n = 6). The intensity of TRPM2 was quantified with ImageJ. Scale bar, 20 m. The data are shown as means SEM; two-tailed Students t tests; *P < 0.05, **P < 0.01, and ***P < 0.001 versus the indicated group.

It has been reported that many receptors are thermally sensitive (10). To verify heat sensitivity, we housed pregnant mice with E13.5 fetuses at 38C for 2 hours for 3 days. Control pregnant mice were kept at room temperature. After 3 days (i.e., E15.5), RNA was extracted from the cerebral tissues of fetal mice. We detected the RNA levels of several receptors associated with heat (10, 22) and observed that in mice subjected to heat stress, the mRNA levels of only TRPM2, among the numbers of the TRP family, increased significantly (Fig. 1J). Molecular markers of heat-sensitive neurons within the preoptic hypothalamus were also affected. BDNF and PACAP mRNA levels increased (fig. S1D), which is consistent with previous studies (23). To examine the specific expression pattern of TRPM2 in the early embryonic brain, we conducted immunofluorescence and colocalization analyses. In vivo, the brain sections of E13.5 and E15.5 mice were collected and stained with antibodies against TRPM2 and the two neural progenitor markers, namely, NESTIN (24) and SOX2 (sex-determining region Yrelated HMG box 2). TRPM2 was observed to be colocalized with NESTIN-positive and SOX2-positive progenitor cells and resided in the VZ/SVZ of the cerebral cortex in both E13.5 and E15.5 brain sections from mice housed at room temperature (Fig. 1K and fig. S1E). In addition, in vitro, we observed that TRPM2 was coexpressed with NESTIN and SOX2 in primary mouse NSCs derived from E12.5 cerebral tissues and cultured in proliferation medium for 2 days (Fig. 1L). Next, to investigate TRPM2 expression at different developmental stages, we harvested cerebral tissues from E13.5, E15.5, and E18.5 and analyzed them using Western blotting. The results revealed that TRPM2 expression gradually increased from E13.5 to E18.5 (fig. S1, F and G). We also investigated TRPM2 transcription in vivo using cortical tissues and in vitro using NPCs cultured under differential or proliferative conditions. Reverse transcription polymerase chain reaction (RT-PCR) was performed on RNA extracted from the tissues or the NPCs. All data indicated that the mRNA levels of TRPM2 showed an obvious up-regulation as embryonic development proceeded (fig. S1, H to J). In addition, another group of pregnant mice was housed at 38C for 2 hours for 3 days at E15.5. Heat-treated mice showed a marked augmentation of TRPM2 expression in the VZ/SVZ of the neocortex compared with that in control mice (Fig. 1, M and N). Overall, these findings suggest that TRPM2, especially during heat stress, plays an important role in modulating NSC neurogenesis during embryonic cortical development.

On the basis of the distinctive expression pattern of TRPM2 in NSCs, we explored whether TRPM2 plays a unique role in neurogenesis during embryonic brain development. We generated a TRPM2-targeting short hairpin RNA (shRNA) plasmid and a TRPM2-overexpressing lentiviral-based vector to effectively silence and augment TRPM2 expression, respectively, in neural progenitors. In NPCs (Fig. 2, A and B, and fig. S1M), N2A cells (fig. S1, L and O), and 293FT cells (fig. S1N) treated with our constructs, Western blotting confirmed TRPM2 knockdown or overexpression. To verify our strategy, we further confirmed TRPM2 shRNA knockdown efficiency by real-time PCR analysis in NSCs, and the analysis showed that TRPM2 levels were effectively suppressed (fig. S1K). Next, we investigated whether TRPM2 disturbs cell distribution in vivo using IUE. In E13.5 mice, brains were injected and electroporated with the TRPM2 shRNA or control plasmid, and the mice were sacrificed at E16.5 for phenotypic analysis. We observed no obvious change in the distribution of GFP-positive cells across the cerebral cortex (fig. S2, A and B). However, the more interesting observation was that when maternal mice were placed in a 38C temperature-controlled incubator for 2 hours from E14.5 to E16.5, TRPM2 knockdown resulted in an obvious reduction in the number of GFP-positive cells in the VZ/SVZ and a corresponding increase in the number of GFP-positive cells in the CP (Fig. 2, C and D). When a 39C temperature-controlled incubator was used, similar results were obtained (fig. S2, C and D). To observe more long-term effects, we performed IUE at E13.5 to E17.5 and comparable GFP-positive cell distributions were observed (fig. S2, E and F). In addition, we also sought to determine whether the knockdown of TRPM2 has a possible effect on cell migration. IUE experiments are frequently used to monitor cell migration during embryonic cerebral development (2527). Then, we performed an E15.5-to-E19.5 IUE experiment in mice at room temperature and an E14.5-to-E18.5 IUE experiment in mice exposed to heat (fig. S2, G to I) and found that there was nearly no difference in GFP distribution from the VZ/SVZ to the CP between the control and TRPM2 knockdown groups. These results jointly eliminated the influence of TRPM2 depletion on cell migration. Thus, the data suggest that TRPM2 may take part in regulating neurogenesis during heat stress.

(A) Western blot analysis confirmed the knockdown (empty pSicoR shRNA was used as a control) of TRPM2 in cultured NSCs. -Actin was used as a control. (B) The graph shows that TRPM2 expression levels were effectively knocked down in primary NSCs by TRPM2-shRNA (n = 6). (C and D) TRPM2 knockdown alters the distribution of cells in the cerebral cortex during heat stress. A control or TRPM2 shRNA plasmids were microinjected and electroporated into the brains of E13.5 mice, and brains were collected on E16.5. During the process, the mice were exposed to 38C for 2 hours per day from E14.5 to E16.5. The GFP-positive cell populations in each region are displayed in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. (E and F) The number of TUJ1+GFP+ cells is augmented in TRPM2 shRNAtreated animals subjected to heat stress. Brain slices from E16.5 mice were stained with an antibody against TUJ1. The population of TUJ1+GFP+ cells relative to the total population of GFP+ cells is shown in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. (G and H) The number of MAP2+GFP+ cells is slightly increased in TRPM2 shRNAtreated animals in hyperthermia. E16.5 brain slices were stained with an anti-MAP2 antibody. The population of MAP2+GFP+ cells relative to the total population of GFP+ cells is shown in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. (I) Silencing TRPM2 induces NPC terminal mitosis during heat stress. A TRPM2 shRNA or control plasmid was injected and electroporated into E13.5 mouse brains. BrdU was gently injected 24 hours after electroporation at E14.5, and the electroporated brains of the embryos were collected for analysis at E18.5. Immunohistochemical analysis was performed using anti-BrdU and anti-CUX1 antibodies. During the process, the mice were exposed to 38C for 2 hours per day from E14.5 to E18.5. The arrowheads represent BrdU+/GFP+ cells, and the arrows represent GFP+BrdU+CUX1+ cells. Scale bar, 20 m. (J) Bar graph displaying the population of BrdU+GFP+ cells relative to the total number of GFP-positive cells in the CP (n = 6 embryos from four different mothers). (K) Quantification of the population of GFP+BrdU+CUX1+ cells relative to the population of GFP+BrdU+ cells (n = 6 embryos from four different mothers). The data are shown as means SEM; two-tailed Students t tests; *P < 0.05, **P < 0.01, and ***P < 0.001 versus the indicated group.

On the basis of the reduction in the number of GFP-positive cells in the VZ/SVZ, which enriches NPCs, we considered the possibility that TRPM2 plays a vital role in modulating NSC proliferation in hyperthermia. To address this possibility, we injected BrdU into pregnant mice 2 hours before the collection of electroporated embryonic brains. In TRPM2 knockdown mice, heat stress at E13.5 to E16.5 led to a marked reduction in the percentage of GFP+BrdU+ cells (fig. S3, A to C), the percentage of GFP+BrdU+PAX6+ cells (fig. S3, D and E), the expression of mitotic marker PH3 (fig. S3, F and G), and the expression of TBR2 (fig. S3, H and I) in NPCs residing in the VZ/SVZ.

Together, these results indicate that TRPM2 is vital for maintaining the NSC pool. To further explore whether a decrease in NPC proliferation leads to precocious cortical neurogenesis, we analyzed cell cycle exit. After electroporating control or TRPM2-shRNA plasmids into embryonic brains at E13.5, BrdU was injected 24 hours before the collection of electroporated brains from embryos on E15.5 and from E14.5 to E16.5. During the process, the pregnant mice were kept at 38C for 2 hours per day. Next, we stained brain slices with antibodies against BrdU and the proliferative marker KI67 to evaluate cells that precociously exit the cell cycle. We observed a substantial augmentation of the indicator of cell cycle exit in the TRPM2-silenced group that was subjected to heat stress, confirming that the elimination of TRPM2 facilitated cell cycle exit in response to hyperthermia (fig. S4, A to C).

To verify the possibility that TRPM2 knockdown NPCs that exit the cell cycle during heat stress may differentiate prematurely into neurons, we stained brain sections with an antibody against TUJ1 (-III-tubulin, a neuronal marker) to label neurons. Analysis revealed an obvious change in the percentage of TUJ1+/GFP+ cells in brain slices from TRPM2 knockdown mice subjected to heat stress (Fig. 2, E and F). We also observed a remarkable increase in the number of cells expressing the neuronal or upper layer markers MAP2+/GFP+ (Fig. 2, G and H), SATB2+/GFP+ (fig. S4, D and E), and CUX1+/GFP+ (fig. S4, F and G) and a decrease in the number of cells expressing CTIP2 (a marker of deep layer neurons)+/GFP+ (fig. S4, I and J) compared to those in control brain slices, suggesting an increase in the differentiation of NSCs. We also birthdated neurons using BrdU to investigate whether TRPM2 knockdown accelerates the terminal mitosis of premature neural progenitors in mice challenged with heat. As previously described (28), BrdU was injected into the abdominal cavity of pregnant mice 24 hours after the electroporation of E14.5 fetuses, and the electroporated brains of the embryos were collected for analyses at E18.5 (fig. S4H). Because BrdU labels dividing cells in the S phase (29), the label becomes diluted and gradually disappeared upon the self-renewal of NPCs. Only cells that differentiate into neurons within the CP layer during their final mitotic division are permanently labeled. By staining with an antibody against BrdU, we observed a marked increase in the number of BrdU+/GFP+ (Fig. 2, I and J) cells in the TRPM2 shRNAtreated brains compared with control shRNAtreated brains. When colocalized with the outer cortical layer marker CUX1, a significant change in the percentage of CUX1+GFP+BrdU+ cells relative to that of GFP+BrdU+ cells in the TRPM2 shRNAtreated group was observed. These results indicate that more BrdU-labeled NPCs differentiated into CUX1-positive neurons in the CP in the TRPM2 shRNAtreated group (Fig. 2K). Collectively, these findings effectively demonstrate that during heat stress, TRPM2 loss of function results in augmented terminal mitosis and enhanced cortical neuronal differentiation.

To verify the role of TRPM2 in neuron development under conditions of heat, we conducted an in vitro experiment using cultured primary NSCs. NPCs obtained from the E12.5 cerebral cortex were infected with either a control or TRPM2 shRNA plasmidpackaged lentivirus. After 24 hours, the cells were then incubated at 38C for 3 days in proliferative medium and finally stained with antibodies against TUJ1 and KI67. We observed an obvious increase in the number of GFP+TUJ1+ cells (fig. S5, A and B) and a marked decrease in the number of GFP+KI67 + cells (fig. S5, C and D) in TRPM2-deficient cells compared with control cells, supporting our in vivo findings. However, when NPCs were incubated at 37C for 3 days, we observed no obvious change in the percentage of GFP+TUJ1+ cells in the TRPM2-deficient cells (fig. S6, H and I).

To further investigate the effects of TRPM2 on NPC morphology during heat stress, we kept NSCs acquired from E12.5 brains in differentiation medium at 38C for 3 days. Using confocal imaging, we observed that compared with control NSCs, TRPM2 knockdown NSCs exhibited longer neurite outgrowth and increased branching after hyperthermia (fig. S5, H to J).

In addition, IUE was performed at E13.5, and the GFP-positive region of the brains from the embryo was collected and digested 2 days after electroporation at E15.5. During E14.5 to E15.5, the pregnant mothers were held at 38C for 2 hours per day. Embryonic GFP-positive brain cells were acquired using fluorescence-activated cell sorting and then cultured for 2 days in proliferative medium at 38C. Notably, TRPM2-silenced cells obtained from embryos whose mothers were heat-challenged showed prominent branching and longer neurite outgrowth compared with empty vectortreated cells (fig. S5, E to G). Jointly, these results suggest that TRPM2 can inhibit neuronal development during heat stress and is required for maintaining stem cell self-renewal.

In E13.5 mice electroporated with a TRPM2 overexpression vector, we observed a prominent increase in the number of GFP-positive cells residing in the VZ/SVZ and a corresponding decrease in the number of GFP-positive cells in the CP at E16.5 when pregnant mothers were subjected to heat stress for 2 hours from E14.5 to E16.5 (fig. S6, A and B). Compared to the normal expression of TRPM2, TRPM2 overexpression during heat stress also led to more BrdU-positive cells in the VZ/SVZ (fig. S6, C to E), supporting a role for TRPM2 in promoting NSC proliferation. In addition, TRPM2 overexpression was found to rescue abnormal NPC distribution caused by the depletion of TRPM2 in vivo (fig. S6, F and G), demonstrating that TRPM2 is required for the proliferation of NPCs during heat stress.

To further explore the phenotype of TRPM2 knockout mice, we generated mice using the CRISPR-Cas9 system through zygote microinjection. The coding sequence (CDS) of TRPM2 is located in exon 3, but not exon 1. After CRISPR editing, a termination codon was introduced near the start codon in the CDS (Fig. 3A). Genotyping PCR (Fig. 3B), Western blotting (fig. S7A), and real-time PCR (fig. S7B) were all performed to identify the knockout efficiency at the genome, protein, and RNA levels, respectively. We verified the knockout of TRPM2 in pregnant TRPM2 knockout mice exposed to hyperthermia at E14.5 to E16.5 by immunostaining E16.5 brain slices with an antibody against TRPM2 (fig. S7C). In addition, by immunostaining with an antibody against cleaved caspase-3, we observed that, in hyperthermia, there was no significant difference in the number of cleaved caspase-3+ cells per field between E16.5 TRPM2+/+ and TRPM2/ brain slices, suggesting that TRPM2 knockout had no effect on cell apoptosis under conditions of heat (fig. S7, D and E).

(A) Schematic diagram of the generation of TRPM2 knockout mice. (B) Genotyping of TRPM2+/+ and TRPM2/ mice. The results show that the PCR products of TRPM2+/+ and TRPM2/ were 1291 and 511 base pairs (bp), respectively. WT, wild type. (C and G) E16.5 brain slices from TRPM2+/+ and TRPM2/ mice were stained with DAPI and an antibody against PH3. Heat stress was applied from E14.5 to E16.5. The graph shows the number of PH3-positive cells per 100 m2 in the VZ/SVZ (n = 6). Scale bar, 20 m. (D and H) TRPM2+/+ and TRPM2/ mice underwent 2 hours of BrdU pulse labeling and were sacrificed at E16.5. Brain slices were then stained with antibodies against BrdU and PAX6. The graph shows the number of BrdU+PAX6+ cells per 100 m2 in the VZ/SVZ (n = 6). Scale bar, 20 m. (E and I) Coronal brain slices of E16.5 TRPM2+/+ and TRPM2/ mice were immunostained with an anti-CUX1 antibody. The number of CUX1+ cells per 100 m2 of CP is shown (n = 6). Scale bar, 20 m. (F and J) Representative images of E16.5 cortices showing SATB2-labeled cells. The graph shows the thickness of SATB2+ cells in the upper layer of the CP (n = 6). Scale bar, 20 m. (K) Deletion of TRPM2 leads to abnormal cell distribution and neurogenesis defects during heat stress. Furthermore, these defects were rescued by the constitutive expression of TRPM2 in the developing brain. A GFP-expressing control vector or TRPM2 overexpression vector was microinjected and electroporated into E13.5 mouse brains. Heat stress was administered from E14.5 to E16.5 for 2 hours a day. The brains were collected on E16.5 and stained for TUJ1. (L) The population of GFP-positive cells in each region is displayed in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. (M) The population of TUJ1+ GFP+ cells among GFP+ cells is displayed in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. The data are shown as means SEM; two-tailed Students t tests; *P < 0.05, **P < 0.01, and ***P < 0.001 versus the indicated group.

Next, we obtained E16.5 TRPM2+/+ or TRPM2/ embryonic brains from mothers that had been housed at 38C for 2 hours per day from E14.5 to E16.5. By staining analysis, we observed fewer neural progenitors expressing PH3 (Fig. 3, C and G) and BrdU/PAX6 (Fig. 3, D and H) in the VZ/SVZ and more neurons expressing CUX1 (Fig. 3, E and I) and SATB2 (Fig. 3, F and J) in the CP in TRPM2 knockout brain slices. In addition, when immunostaining for TRPM2 together with NESTIN or TUJ1 was performed on E16.5, we found that the expression of NESTIN was decreased, while the level of TUJ1 was observably augmented after the deletion of TRPM2 in hyperthermia (fig. S7, F and G). Consistently, when mice were housed at 38C for 2 hours per day from E14.5 to E18.5, more neurons expressing CUX1 were observed in the CP in TRPM2 knockout brain slices both on postnatal day 0 (P0) and P6 (fig. S8, F to I), which suggests that the heat-mediated shift in the proliferation to differentiation ratio upon TRPM2 knockout has a consistent and longer-term effect in later stages of development. However, in brain slices obtained from embryos of mothers who had been housed at room temperature, we did not find an obvious difference in TUJ1 staining at P0 between the wild-type and TRPM2 knockout groups (fig. S8J). Consistently, progenitors isolated from hyperthermic E12.5 TRPM2/ embryos developed longer neurites and more branching after culture in differentiation medium for 3 days than those of hyperthermic E12.5 TRPM2+/+embryos, while room temperature embryos lacked these phenotypes (fig. S8, A to E). These observations suggest that TRPM2 knockout and hyperthermia accelerate neuron development. In addition, NSCs obtained from E12.5 TRPM2/ embryos formed smaller neurospheres than those of controls in hyperthermia, but not room temperature conditions, suggesting that the loss of TRPM2 inhibits NPC proliferation during hyperthermia (fig. S7, K to M). To validate the function of TRPM2 during cortical neurogenesis in times of hyperthermia, we electroporated the brains of fetal TRPM2+/+ and TRPM2 / mice with control plasmids and brains of fetal TRPM2 / mice with TRPM2 overexpression plasmids on E13.5. Then, on E16.5, we collected brain samples from mice that had been exposed to heat stress for 2 hours from E14.5 to E16.5. By staining with an anti-TUJ1 antibody, we found that TRPM2/ mice not only exhibited an aberrant distribution of GFP-positive cells in three cortical layers but also showed a prominent increase in the proportion of GFP and TUJ1double positive cells compared with that in TRPM2+/+ mice, which is reminiscent of TRPM2 knockdown mice subjected to heat stress. Moreover, forced expression of TRPM2 in TRPM2/ mice in hyperthermia could rescue the abnormalities evoked by the ablation of TRPM2, i.e., both the distribution and ratio of GFP+ TUJ1+ cells (Fig. 3, K to M). In addition, we also compared the distribution and ratio of GFP+ TUJ1+ cells between TRPM2/ mice at room temperature and TRPM2/ mice in hyperthermia groups. The results revealed that, upon exposure to hyperthermia, TRPM2/ mice displayed a significant increase in the number of GFP-positive cells in the CP and the percentage of TUJ1+GFP+ cells (fig. S7, H to J). These findings demonstrate the vital role of TRPM2 during embryonic neurogenesis. In addition, the consistent phenotype of TRPM2 knockout excludes the possibility of potential off-target effects of TRPM2 shRNA in knockdown experiments. To investigate the effect of TRPM2 deficiency on differentiating neurons in hyperthermia, we conducted an in vitro experiment using cultured primary neurons. The neurons were isolated from P0 hyperthermic TRPM2+/+ and TRPM2/ embryos and cultured in differentiation medium for 3 days. By staining with an antibody against TUJ1, we observed no obvious difference between the wild-type and TRPM2 knockout groups in terms of neurite length or number of branches (fig. S8, K to M), suggesting that TRPM2 deficiency induces no phenotype in neurons under heat stress. We also analyzed other stimuli, such as treatment with NaCl (fig. S8, N and Q), change in pH (fig. S8, O and R), and X radiation exposure (fig. S8, P and S), and subsequently found that TRPM2 was not activated by these stimuli. Overall, these findings indicate that well-regulated embryonic cortical development can be disturbed in hyperthermic conditions when TRPM2 is deleted.

To further detail how TRPM2 affects the developing brain in hyperthermia, we sequenced RNA (RNA-seq) to analyze transcriptome-wide changes that arise from the loss of TRPM2. Total RNA was acquired from the cortical tissue of E16 TRPM2 knockout and wild-type mice with mothers that were housed at 38C for 2 hours per day from E14.5 to E16.5. Sequencing was repeated twice for each sample to increase the reliability of the sequencing results. Gene Ontology (GO) analysis revealed that down-regulated genes were associated with cell proliferation and temperature stimuli, including the canonical Wnt signaling pathway, neuronal stem cell division, the detection of temperature stimuli involved in sensory perception, and the negative regulation of cell differentiation. The up-regulated genes were associated with neurogenesis, the regulation of neuronal development, and cell fate commitment (fig. S9A). These data jointly suggest a crucial role for the thermal sensor protein TRPM2 in cortical neurogenesis during hyperthermia. Next, we explored how the deletion of TRPM2 affects neurogenesis at the molecular level during heat stress. Among the differentially expressed genes identified by genome analyses, we selected genes that changed consistently in both sequencing results and finally selected SP5 as a downstream target (fig. S9B and Fig. 4A). To confirm the results of RNA-seq, we performed RT-PCR (fig. S9C) and Western blotting (fig. S9D) and observed that SP5 expression was significantly decreased in samples obtained from the cortex of TRPM2 knockout mice that had experienced heat stress. SP5 is a transcription factor that is downstream of Wnt signaling (17, 19), but the function of SP5 in cortical neurogenesis during hyperthermia has not yet been identified.

(A) The volcano plot indicates differentially expressed genes. The red dots represent up-regulated genes, while the green dots represent down-regulated genes. SP5 is one of the notably down-regulated genes. (B and C) SP5 knockdown results in an abnormal cellular distribution during heat stress. The bar graph shows the population of GFP+ cells in the CP, IZ, and VZ/SVZ (n = 6 embryos from four different mothers). Scale bar, 50 m. (D) Western blot results showing the change in the expression of TRPM2, total -catenin, phosphorylated -catenin, SP5, TUJ1, PH3, and PCNA during heat stress in TRPM2 knockout embryos. Heat stress was applied from E14.5 to E16.5 for 2 hours per day. -Actin was used as the control (n = 3). (E) TRPM2 knockout in vivo during hyperthermia increases GSK3 activity (n = 3). (F) The suppression of TRPM2 in NSCs during heat stress intensifies GSK3 activity (n = 3). (G) Calmodulin (CAM) interacts with GSK3 in hyperthermia (n = 3). (H) Western blot analysis showing changes in the expression levels of TRPM2, total -catenin, phosphorylated -catenin, and SP5 between the brains of room temperature and hyperthermia-exposed embryonic mice. -Actin was used as the loading control (n = 3). (I and J) The intracellular calcium ion concentration increases upon exposure to 38C. After neural stem cells were isolated from the E12.5 cortex cultured at 37C or 38C overnight, they were incubated for 30 min with Fluo-3, and the intracellular calcium fluorescence was quantified with a confocal LSM780 microscope. The graph shows the relative Fluo-3 intensity (n = 30). Scale bar, 15 m. (K) Calcium concentration reduction is caused by TRPM2 knockdown in hyperthermia. NSCs isolated from the E12.5 cortex were infected with a control or TRPM2-shRNA plasmid (red)packaged lentivirus. After 6 hours, the cells were cultured at 38C overnight; then, the calcium concentration was measured (n = 3). Scale bar, 5 m. (L) Western blots showing the expression levels of Flag, total -catenin, and phosphorylated -catenin in primary NSCs with constitutively expressing CAM in hyperthermia conditions. -Actin was used as a control (n = 3). The data are shown as means SEM; two-tailed Students t tests; ***P < 0.001 versus the indicated group.

To investigate the function of SP5 in embryonic brain development, we first stained brain slices with a specific fluorescent antibody against SP5. The in vitro results showed that SP5 was expressed in the nuclei of primary mouse NSCs and was colocalized with progenitor markers, such as NESTIN and SOX2 (fig. S9G). Consistently, SP5 was expressed in vivo in NESTIN-positive NSCs in the VZ/SVZ of the E13.5 cortex (fig. S9H). Furthermore, shRNAs targeting SP5 were constructed, and they effectively silenced the expression of SP5 (fig. S10A). In addition, samples from heat stressexposed mice in which the expression of SP5 was silenced showed an increased number of GFP-positive cells in the CP and a decreased number of GFP-positive cells located in the VZ/SVZ (Fig. 4, B and C). However, the redistribution of GFP-positive cells was not obvious in control mice from mothers that had been housed at room temperature (fig. S10, F and G). Immunostaining for KI67 also showed that fewer GFP+KI67+ cells were observed in the VZ/SVZ in SP5 knockdown mice that had been exposed to heat stress (fig. S10, B and C). In addition, we also found that the percentage of TUJ1-positive cells was obviously increased in neural progenitors that had been infected with an SP5 shRNApackaged lentivirus and had been exposed to hyperthermia (fig. S10, D and E). Overall, these data confirm that SP5 acts downstream of TRPM2 to modulate neurogenesis during heat stress.

To further confirm and elucidate the specific mechanisms by which TRPM2 exerts its effect on NPC proliferation in hyperthermia, we monitored the relative mRNA levels of SP5 and several molecular markers associated with proliferation. Transcription analysis revealed that -catenin mRNA levels were reduced by 40% in TRPM2 knockout NPCs from mice exposed to hyperthermia, while the levels of REST, Hes5, SOX2, CyclinD1, Foxg1, and Olig2 were unchanged (fig. S9C). These findings suggest that -catenin may work together with TRPM2 to regulate embryonic neurogenesis during heat stress. To compare the transcription results to translational outcome, we conducted Western blot analysis. Protein was obtained from E16 cortical tissue from TRPM2 knockout and wild-type mice that were housed at 38C for 2 hours per day from E14.5 to E16.5. Western blot analysis showed an obvious reduction in SP5 and -catenin expression levels. We also found that the phosphorylation levels of -catenin were augmented in TRPM2 knockout mice exposed to hyperthermia. In addition, decreases in expression of the proliferative markers PH3 and PCNA (proliferating cell nuclear antigen) and an increase in the expression of the neuronal marker TUJ1 in TRPM2 knockout mice clarified the role of TRPM2 in embryonic neurogenesis in hyperthermia (Fig. 4D). We obtained similar results in TRPM2 knockdown or TRPM2 overexpression primary NSCs exposed to 38C (fig. S9, E and F). In TRPM2 knockdown NPCs, immunostaining for total -catenin verified that its expression was reduced during heat stress (fig. S10, H and I). We did not observe such an obvious change under room temperature conditions (fig. S6J). Intrigued by the altered phosphorylation levels of -catenin in TRPM2 knockout mice exposed to hyperthermia, we tested the activity of glycogen synthase kinase 3 (GSK3), which is a serine/threonine kinase associated with -catenin phosphorylation. On the basis of the fact that GSK3 activity requires the autophosphorylation of Tyr216 (30), we evaluated protein levels and protein modifications. In TRPM2 knockout mice exposed to hyperthermia, we observed an obvious increase in Tyr216 phosphorylation, suggesting that TRPM2 may negatively regulate GSK3 activity (Fig. 4, E and F). The constitutive overexpression of TRPM2 during hyperthermia intensifies GSK3 activity (fig. S10K). In addition, Western blot analysis showed an increase in the expression of TRPM2, total -catenin, and SP5 and a decrease in the phosphorylation of -catenin (Fig. 4H). Together, these findings suggest that TRPM2 may modulate SP5 transcription by inhibiting the phosphorylation of -catenin and activating -catenin expression.

Intracellular calcium signaling plays key roles in neural development, including neuronal plasticity, neuronal survival, and neurogenesis (31). Studies have shown that intracellular calcium affects the -catenin pathway (32). To further investigate the mechanisms by which TRPM2 plays a role in activating -catenin expression, we measured the calcium ion concentration in NSCs using a confocal microscope and a calcium-sensitive dye. We observed that, when the cells were cultured at 38C overnight, the intracellular calcium levels were significantly increased (Fig. 4, I and J). However, when cells were transfected with the TRPM2-sh1 plasmid with red fluorescent protein (RFP), intracellular calcium decreased (Fig. 4K), suggesting that TRPM2 modulates intracellular calcium. Calmodulin (CAM) is a target of calcium ions within the cell, and once bound to calcium ions, CAM is activated and serves as part of the calcium signal transduction pathway by modulating interactions with various target proteins (33). In our study, we found that CAM interacted with GSK3 (Fig. 4G), and Western blotting showed that phosphorylated -catenin levels were reduced, while total -catenin expression was slightly increased when CAM was overexpressed during heat stress (Fig. 4L). Therefore, these findings suggest that thermal stimuli activate TRPM2, which increases intracellular calcium. Calcium ions can then bind to CAM, thus inhibiting the levels of phosphorylated -catenin and simultaneously activating the expression of -catenin.

On the basis of these results, we suggest that -catenin may enter the nucleus, bind to the SP5 promoter, and modulate the expression level of SP5 during heat stress. To test this hypothesis, we used a luciferase plasmid containing 2 kb of the SP5 promoter and measured luciferase activity (Fig. 5A). We also generated a vector that overexpressed -catenin with a hemagglutinin (HA) tag and characterized its efficiency by Western blotting (fig. S10J). At 39C, we observed more than twofold increase in luciferase activity in cells treated with the -catenin vector compared with cells treated with the empty vector, demonstrating that -catenin binds to the SP5 promoter to exert its function (Fig. 5A). To further determine the specific binding site, we used a chromatin immunoprecipitation (ChIP) assay (Fig. 5B). At 39C, in cells in which -catenin was constitutively expressed, the binding of -catenin 0.5 kb from the SP5 promoter increased, and binding decreased as the distance to the transcription start site increased (Fig. 5B). These differences were not observed at 37C (Fig. 5B). In addition, we analyzed the promoters of other -catenin target genes, such as Axin2 and CyclinD1, in hyperthermia and observed that there was almost no binding of -catenin (fig. S10, L and M), suggesting specificity for SP5.

(A) Flow chart of the luciferase assay in which the SP5 promoter was cloned into the psiCHECK-2 vector. (A) 293FT cells were transfected with an empty vector or a -cateninexpressing vector. Both groups were cotransfected with an SP5 promotercontaining psiCHECK-2 vector and cultured at 39C. After 36 hours of transfection, the relative luciferase activity was quantified and is shown in the bar graph (n = 4). (B) Four pairs of primers were designed for 0.5, 1, and 2 kb from the SP5 transcription start sites and SP5 CDS for ChIP analysis. (B) NPCs cultured in vitro at 39C were infected with a -cateninHAcontaining lentivirus and then pulled down using immunoglobulin G (IgG) or HA-incubated magnetic beads. The relative amount of SP5 promoter was detected via ChIP and real-time PCR and is shown in the bar graph (n = 3). (B) NPCs cultured in vitro at 37C were infected with a -cateninHAcontaining lentivirus and then pulled down with IgG- or HA-incubated magnetic beads. The relative amount of SP5 promoter was determined by ChIP and real-time PCR and is shown in the bar graph (n = 3). (C to F) SP5 overexpression rescues the cortical neurogenesis defects evoked by TRPM2 knockdown (C and D) or knockout (E and F) in hyperthermia. After electroporation (E13.5) and heat stress (E14.5 to E16.5), E16.5 brain slices were stained with anti-TUJ1 antibody. The bar graphs show the percentage of TUJ1+GFP+ cells relative to the total number of GFP+ cells (n = 6 embryos from four different mothers). Scale bars, 50 m. (G) Working model of TRPM2 function in modulating cortical neurogenesis during heat stress. TRPM2 during heat stress increases calcium influx, which inhibits the phosphorylation of -catenin and induces -catenin enrichment on the SP5 promoter, thereby promoting NPC proliferation. The data are shown as means SEM; two-tailed Students t tests; *P < 0.05, **P < 0.01, and ***P < 0.001 versus the indicated group.

To decipher the connection between TRPM2 and SP5 in neurogenesis during heat stress, we performed rescue experiments. We observed that the constitutive expression of SP5 increased the cell populations residing in the VZ/SVZ and ameliorated the irregularity of both the distribution and percentage of GFP+ TUJ1+ cells caused by TRPM2 knockdown (Fig. 5, C and D) and knockout (Fig. 5, E and F) during heat stress in vivo. Therefore, these data demonstrate that SP5 acts downstream of TRPM2 to modulate early cortical development in hyperthermia. Together, our data supported the notion that, during heat stress, TRPM2 increases SP5 levels via the stabilization of -catenin enrichment on the SP5 promoter, thus enhancing NPC proliferation (Fig. 5G).

Cortical neurogenesis is a very sophisticated process that is strictly controlled by a great deal of signaling molecules. If any step of this process goes wrong, abnormal brain functions, and thus neurodevelopmental disorders, result (34). Temperature homeostasis is essential for embryo survival, and heat stress disturbs numerous aspects of fetal development and brain function (35). TRPM2, which has been recently identified as a heat activation protein, plays an important role in the heat response. TRPM2 is also a calcium-permeable channel in the plasma membrane, and a growing body of evidence has shown that calcium signaling heavily affects neural progenitor proliferation during embryonic neurogenesis (10, 36). However, no details as to whether or how TRPM2 affects brain neural development under conditions of heat exist. Here, we used TRPM2 shRNA and knockout mice to investigate the specific functions of TRPM2 in NPC proliferation and differentiation, cortical neuronal morphology, and the mechanisms guiding embryonic neurogenesis under hyperthermic conditions.

In our study, we first confirmed the thermal sensitivity of TRPM2 and then observed that TRPM2 is expressed in NSCs. When expressed during heat stress, TRPM2 augments NPCs in the E15.5 cerebral cortex, providing clues regarding its effect on neurogenesis during hyperthermia. Furthermore, we found that heat stress changes cellular distribution and facilitates NSC proliferation. Previous studies have shown that at room temperature, TRPM2 loss of function leads to increased axonal growth to promote neuronal differentiation (37). Here, we demonstrated that TRPM2 can exert its function earlier, specifically at E13.5, and that during heat stress, the loss of TRPM2 has a more powerful effect on facilitating cortical neurogenesis. However, at room temperature, the phenotype is not obvious. Our data indicate that TRPM2 deficiency in hyperthermia results in a change in cell distribution and proliferation defects with a sharp drop in the NSC pool. We also found that the depletion of TRPM2 during heat stress increases cell cycle exit and premature cell terminal mitosis, ultimately promoting neurons to a more differentiated state. Both proliferation defects and abnormalities in neuronal morphogenesis lead to severe brain illness, such as autism and schizophrenia (38, 39). In addition, we were able to eliminate the influence of cell migration and apoptosis during hyperthermia by knocking out TRPM2. However, why the TRPM2 knockdown phenotype observed during heat stress is more obvious than the phenotype observed under room temperature conditions still needs to be explored.

To investigate the mechanisms underlying the unique phenotype caused by the loss of TRPM2 and hyperthermia, we searched for downstream targets using RNA-seq analysis and found that SP5 expression was decreased upon TRPM2 knockout and hyperthermia. SP5 is a member of the SP1 family of transcription factors, but its function in embryonic brain development is still unclear.

Our research shows that SP5 is abundant in NPCs and that, under conditions of heat, TRPM2 deficiency inhibits SP5 expression from E13.5 to E16.5. This leads to a decrease in the number of GFP-positive cells residing in the VZ/SVZ and results in the promotion of neuronal differentiation. To further decipher how TRPM2 enhances SP5 expression in hyperthermia, we analyzed some signaling molecules and found that total -catenin expression was significantly down-regulated, while the phosphorylation of -catenin was obviously increased upon TRPM2 deficiency and heat stress. -Catenin, which functions in canonical Wnt signaling, is abundant in NSCs and contributes to the modulation of NSC expansion (15). However, specific mechanisms of the protein are not entirely clear. Previous studies have indicated that Wnt/-catenin is associated with intracellular Ca+ (32). Given that TRPM2 is a calcium-permeable channel, we investigated calcium ions during heat stress, and our data showed a decrease in intracellular Ca+ levels upon TRPM2 knockout. Moreover, the overexpression of CAM inhibited the phosphorylation of -catenin and augmented the expression of -catenin. Using a luciferase and ChIP assay, we also confirmed that -catenin binds to the SP5 promoter during heat stress. Unexpectedly, our results indicated that the overexpression of SP5 ameliorates the defects evoked by TRPM2 loss of function in hyperthermia. However, in the future, the current hyperthermia model needs to be further improved because in human, such as fever response, immune system component may take part in this model.

In summary, our findings uncovered a novel mechanism by which TRPM2, a thermo-sensor protein, governs embryonic neural development during heat stress. Furthermore, the neuronal morphology abnormalities in TRPM2 knockout mice exposed to hyperthermia during embryonic development may provide novel insights into neurological disorders associated with heat stress, including maternal fever, and reveal new strategies for treatment. In terms of the mechanism, we found that when TRPM2 is activated by heat and intracellular calcium binds to CAM, the phosphorylation of -catenin is inhibited. Accumulating -catenin then binds to the SP5 promoter to ultimately enhance NPC proliferation.

Pregnant ICR mice were obtained from Vital River Laboratories. All animal-related experiments were conducted in line with the Animal Care and Use Committee of Institute of Zoology, Chinese Academy of Sciences. TRPM2 knockout mice used in our experiments were generated and kept in the Experiment Animal Center of Institute of Zoology, Chinese Academy of Sciences.

To construct shRNA-expressing plasmids, the oligonucleotides were inserted into the pSicoR-GFP (Addgene, 12093) or pSicoR-TOMATO lentiviral vector. The sequences of shRNAs targeting TRPM2 were as follows: TRPM2-sh1, AACCTTAGCTCATGGATTC (13); TRPM2-sh2, GACCTTCTCATTTGGGCCGTT (Sigma). The sequences of SP5 shRNAs were as follows: SP5-sh1, GGATTCAAAGGATTTGCTTTC (17); SP5-sh2, CCCGTCGGACTTTGCACAG (Sigma). The full-length complementary DNAs (cDNAs) of mouse TRPM2, SP5, and CAM were obtained via PCR and cloned into the Flag-tagged pCDH (System Biosciences, CD511B-1) vector for lentivirus packaging.

Human 293FT cells and mouse N2A cells were cultured in Dulbeccos modified Eagles medium (DMEM) that contained 1% penicillin-streptomycin (PS) and 10% fetal bovine serum (FBS). Mouse cortical NPCs from E12.5 mouse cortex were maintained in proliferation medium, which contained 50% DMEM/F12 (Invitrogen), 50% neural basal medium (Invitrogen), epidermal growth factor (EGF) (10 ng/ml), basic fibroblast growth factor (bFGF) (10 ng/ml) (Invitrogen), 1% PS, and 2% B27 (without vitamin A).

The production of lentivirus was obtained by transfecting the core and packaging plasmids into 293FT cells using GenEscort I (Nanjing Wisegen Biotechnology). The virus was gathered at 24, 48, and 72 hours after changing the medium 6 hours after transfection. The primary NSCs for Western blot and immunofluorescence were seeded in 6- or 24-well plates, which were coated with laminin (Invitrogen) and poly-d-lysine (Sigma) (both 10 g/ml) in advance. Twenty-four hours later, half of the medium was changed with proliferation medium without PS. Lentivirus was then added to each well and maintained for 8 hours. Meanwhile, to improve the infection efficiency, polybrene (2 g/ml) was mixed into the medium. Forty-eight hours later, to induce a differentiation state, the medium was displaced with low-glucose DMEM (Gibco) supplemented with 1% FBS (Invitrogen), 1% PS, and 2% B27 (with vitamin A).

IUE was performed as reported previously (40). In brief, pregnant ICR or C57 mice were deeply anesthetized with pentobarbital sodium (70 mg/kg). Subsequently, the recombinant knockdown or overexpression plasmids with a final concentration of 1500 ng/l were mixed with an enhanced GFP plasmid at a ratio of 3:1. In addition, 0.02% Fast Green was included as a tracer. Then, the mixture was microinjected into the lateral ventricle of the embryonic mouse brains using glass capillaries. Five electric pulses of 40 V (950-ms interval; 50-ms duration) were generated using an electroporator (Manual BTX ECM 830) and platinum electrodes. After IUE, the brains of the embryos were collected at E16.5, E17.5, or P1 for further phenotype analysis.

For neural progenitor proliferation analysis, BrdU (50 mg/kg) was injected 2 hours before brain harvesting at E16.5. For neuronal birth dating, BrdU (50 mg/kg) was administrated to pregnant mice at E14.5. For cell cycle exit analysis, BrdU (100 mg/kg) was administrated to pregnant mice 24 hours before brain collection at E15.5.

For heat stress experiments, mice were maintained in their cages, and the cages were put in a large temperature-controlled incubator set at 38 or 39C for 2 hours each day for 2 or 3 days.

Brain slices or cells cultured in vitro were washed with phosphate-buffered saline (PBS) for 5 min, fixed in 4% paraformaldehyde for 20 min, and blocked in 5% bovine serum albumin (Sangon)/PBS containing 1% Triton X-100 (1% PBST) for 1 hour. Subsequently, the primary antibody was diluted with 1% PBST, added, and then incubated at 4C overnight. The following day, the samples to be visualized were rinsed with PBS three times and incubated with secondary antibodies at room temperature for nearly 1.5 hours. The primary antibodies used for immunofluorescence are listed here: rabbit anti-TRPM2 (1:1000; Bethyl Laboratories), rabbit anti-TUJ1 (1:1000; Sigma), mouse anti-BrdU (1:1000; Millipore), rat anti-BrdU (1:1000; Abcam), rabbit anti-CUX1 (1:100; Santa Cruz Biotechnology), rabbit anticleaved caspase-3 (1:1000; Cell Signaling Technology), rabbit anti-PAX6 (1:1000; Millipore), mouse anti-MAP2 (1:1000; Millipore), mouse anti-NESTIN (1:1000; Millipore), rabbit anti-KI67 (1:1000; Abcam), mouse anti-SATB2 (1:300; Abcam), rabbit anti-SP5 (1:200; Bioss), rabbit anti-TBR2 (1:1000; Abcam), rat anti-CTIP2 (1:1000; Abcam), and mouse anti-SOX2 (1:1000; R&D Systems). Secondary antibodies applied were conjugates of Alexa Fluor Cy3, Cy5, or 488 (1:1000; Jackson ImmunoResearch). 4,6-Diamidino-2-phenylindole (DAPI) (2 mg/ml; Sigma) was used for nuclear staining.

Protein was extracted from brain cortical tissue of mouse or cultured cells by lysing with radioimmunoprecipitation assay buffer (Solarbio), with 10 mM phenylmethylsulfonyl fluoride and a protease inhibitor cocktail (Sigma, P8340). Samples were then ultrasonicated and centrifuged at approximately 12,000 rpm for 15 min at 4C. Subsequently, the supernatants were gathered, and protein concentrations were determined using a BCA kit (Thermo Scientific). Next, similar amounts of protein samples were size-separated by 6 to 12% SDSpolyacrylamide gel electrophoresis gels and shifted onto nitrocellulose membranes (Whatman) making use of a semidry transfer system (Bio-Rad). We run multiple gels and normalized to a control. The primary antibodies applied in the Western blots are listed here: rabbit anti-TRPM2 (1:1000; Bethyl Laboratories and Novus Biologicals), rabbit antitotal -catenin (1:1000; Cell Signaling Technology), rabbit antiP-catenin (S33/S37/T41) (1:1000; Cell Signaling Technology), rabbit antinonP-catenin (S33/S37/T41) (1:1000; Cell Signaling Technology), rabbit anti-PCNA (1:500; Santa Cruz Biotechnology), rabbit anti-TUJ1 (1:1000; Bioward), rabbit anti-SP5 (1:500; Bioss), rabbit anti-PH3 (1:1000; Cell Signaling Technology), rabbit anti-TBR2 (1:1000; Abcam), and rabbit anti-Flag (1:1000; Sigma). Secondary antibodies were 800CW Donkey Anti-Mouse IgG (immunoglobulin G), 800CW Donkey Anti-Rabbit, 680LT Donkey Anti-Mouse IgG, and 680LT Donkey Anti-Rabbit IgG (LI-COR Biosciences). Odyssey v3.0 software was used to scan and quantify Western blot bands.

Total RNA was obtained using TRIzol (Invitrogen, 15596) following the manufacturers directions. Reverse transcription of mRNA to first-strand cDNA was achieved using the FastQuant RT Kit (TIANGEN). Quantitative RT-PCR was conducted using the SYBR Green PCR Kit (Takara) with an ABI PRISM 7500 sequence detector system (Applied Biosystems). All reactions were repeated in triplicate for each sample. The primer sequences used for RT-PCR are listed here: TRPM2, AAGGAACACAGACAATGCCTG (forward) and AGGATGGTCTTGTGGTTCGC; TRPM3, TACACCAAAGTCAGCTCCCTG (forward) and GGCCTCTCGTGGAAAGTCAT (reverse); TRPM7, CCCAGCCAAGTTGCAAAAGT (forward) and CTACAGCTTTCTGCTTGCACC (reverse); TRPM8, GTCCTGTGACACCGACTCTG (forward) and CAGTGAGAATCCACGCACCT (reverse); TRPV1, CTCGGATGAATCTGAGCCCC (forward) and GACAACAGAGCTGACGGTGA (reverse); TRPV3, AGTGCTTATAGCAGCGGGTG (forward) and CGTGCAGGATGTTGTTTCCC (reverse); TRPV4, TCCTCTTCTCTTTCCCCGGT (forward) and GTGCCGTAGTCGAACAAGGA (reverse); ANO1, CGAGAAGTACTCGACGCTCC (forward) and TAGTCCACCTTCCGTTTGCC (reverse); TRPA1, TCTGCATATTGCCCTGCACA (forward) and ACTTTCATGCACTCGGGGAG (reverse); BDNF, TACCTGGATGCCGCAAACAT (forward) and GCCTTTGGATACCGGGACTT (reverse); PACAP, ATGACCATGTGTAGCGGAGC (forward) and CGCTGGATAGTAAAGGGCGT (reverse); -catenin, ATCACTGAGCCTGCCATCTG (forward) and GTTGCCACGCCTTCATTC (reverse) (39); SP5, GGCAAGGTGTACGGCAAAAC (forward) and CATAGGTCCCGCGGATTCTC (reverse); REST, GTGCGAACTCACACAGGAGA (forward) and AAGAGGTTTAGGCCCGTTGT (reverse) (41); Hes5, CGCATCAACAGCAGCATAGAG (forward) and TGGAAGTGGTAAAGCAGCTTC (reverse); CyclinD1, GCCTACAGCCCTGTTACCTG (forward) and ATTTCATCCCTACCGCTGTG (reverse) (42); SOX2, GCACATGAACGGCTGGAGCAACG (forward) and TGCTGCGAGTAGGACATGCTGTAGG (reverse); Foxg1, GGCAAGGGCAACTACTGGAT (forward) and CGTGGTCCCGTTGTAACTCA (reverse); Olig2, GGTGTCTAGTCGCCCATCG (forward) and AGATGACTTGAAGCCACCGC (reverse); -actin, GGTGGGAATGGGTCAGAAGG (forward) and AGGAAGAGGATGCGCCAGTG (reverse).

ChIP was performed as follows. To generate the cross-link, in vitro cultured cells were processed with 1% formaldehyde and maintained at room temperature for 10 min. Subsequently, 2.5 M glycine was then added to terminate the cross-link reaction. After washing three times with sterile PBS, the cells were gathered in lysis buffer. Next, the lysates were incubated with 15 l of Dynabeads Protein G (Invitrogen), which was incubated at least 12 hours with 1 g of specific antibody at 4C before incubation. After washing three times with low- and high-salt buffer, the DNA-protein-antibody complex was incubated overnight at 65C to open the covalent bond. Genomic DNA was then obtained using the TIANamp Genomic DNA Kit (TIANGEN Biotech) for subsequent real-time PCR analysis. The primer sequences applied for SP5 promoter are listed here: SP5-CDS, GGCAAGGTGTACGGCAAAAC (forward) and CATAGGTCCCGCGGATTCTC (reverse); SP5-0.5k, AGCTCGGTTGTGGGAGGAA (forward) and TCTTGACAAGCCGCTTGAAG (reverse); SP5-1k, ACCGCTGCCAGGTCGCT (forward) and AGGCAGGGTCAGTCGGC (reverse); SP5-2k, GCTGGGAACCGGTGGCT (forward) and TTGGGAGTATCCTCTTTGGC (reverse); CyclinD1-CDS, TCAAGACGGAGGAGACCTGT (forward) and TTCCGCATGGATGGCACAAT (reverse); CyclinD1-0.5k, CAGCCTCTTCCTCCACTTCC (forward) and AAGCCCTTCTGGAGTCAAGC (reverse); CyclinD1-1k, TCTACTTTAACAATGGTTTGCTGT (forward) and ACAGGGGAAGTCTTGAGAAGG (reverse); CyclinD1-2k, TCAGACATGGCCCTAAACCT (forward) and CATGACCAGTGTGACTCAAAGC (reverse); Axin2-CDS, CAAATGCAAAAGCCACCCGA (forward) and TGCATTCCGTTTTGGCAAGG (reverse); Axin2-0.5k, TACACACTCCCACCACCGA (forward) and ATCTCTGCTCACAGTTTCGGA (reverse); Axin2-1k, TGGAATGCAGTCTATCCCAGC (forward) and AGAAGCTGTGTGACCAGCCA (reverse); Axin2-2k, CCACCACAATCATCCTGGGT (forward) and TCAACTTTAAGGACTGAGGCCA (reverse).

Global transcriptome analysis was conducted by Annoroad Company. Total RNA samples were first tested for quality and quantity using an Agilent 2100 bioanalyzer. After building the library, high-throughput sequencing was used with the Illumina HiSeq 2500 platform. Our RNA-Seq data were deposited in the Gene Expression Omnibus database with the accession number of GSE113954.

The CRISPR-Cas9 system was used to construct TRPM2 knockout mice. During the process, two guide RNAs (gRNAs) (gRNA5, GCCAGTTCTTCTCCGGTCCAAGG; gRNA3, TATTGCTTCGTCGGAGATTGGGG) were used to cleave the whole genome sequence of TRPM2 to approximately 800 base pairs (bp). The genotyping primers designed for the TRPM2 knockout mice were TRPM2-2717F GAAGGGAAACGGGTGGATGT and TRPM2-4007R GCAGGTCTCCTCAACCAGTC. The length of PCR product was 511 or 1291 bp for TRPM2 knockout mice or wild-type mice, respectively.

Apoptotic cells were identified with immunostaining using an antibody targeting cleaved caspase-3.

293FT cells (4 104) were seeded into a 24-well plate and transfected with 0.5 g of luciferase plasmid containing an SP5 promoter and empty vector or with 0.5 g of luciferase plasmid containing an SP5 promoter and -catenin overexpression vector, using GenEscort I (Nanjing Wisegen Biotechnology). Thirty-six hours after transfection, luciferase activity was measured using the Dual-Luciferase Assay System (Promega) and GloMax 96 Microplate Luminometer (Promega).

All images were taken with a Zeiss LSM780 confocal microscope and analyzed with Photoshop CS6 (Adobe). ZEN 2010 was applied for image acquisition and processing. Brightness or expression quantity was measured using ImageJ when needed.

All statistical analyses in this study were performed and plots were generated using GraphPad Prism7.0 software. Results are represented as means SEM. Two-tailed Students t tests and one-way analysis of variance (ANOVA) were used for statistical comparisons. The differences were regarded as statistically significant with *P < 0.05, **P < 0.01, and ***P < 0.001. n.s. means not significant.

Acknowledgments: Funding: This work was supported by grants obtained from the National Science Fund for Distinguished Young Scholars (81825006), CAS Strategic Priority Research Program (XDA16010301), National Key R&D Program of China (2019YFA0110300 and 2018YFA0108402), National Science Foundation of China (31730033 and 31621004), and K. C. Wong Education Foundation. Author contributions: Y.L. performed the experiments, analyzed data, and wrote the manuscript. J.J. conceived and supervised this project. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

View post:
Deficiency of TRPM2 leads to embryonic neurogenesis defects in hyperthermia - Science Advances

Read More...

Hydrogel controls inflammation to speed healing – Futurity: Research News

January 1st, 2020 7:45 pm

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Researchers have established a baseline set of injectable hydrogels that show promise to help heal wounds, deliver drugs, and treat cancer.

Critically, theyve analyzed how the chemically distinct hydrogels provoke the bodys inflammatory responseor not.

The researchers designed the hydrogels to be injectable and create a mimic of cellular scaffolds in a desired location. They serve as placeholders while the body naturally feeds new blood vessels and cells into the scaffold, which degrades over time to leave natural tissue in its place. Hydrogels can also carry chemical or biological prompts that determine the scaffolds structure or affinity to the surrounding tissue.

We dont want zero inflammation; we want appropriate inflammation.

The study demonstrates it should be possible to tune multidomain peptide hydrogels to produce appropriate inflammatory response for what theyre treating.

Weve been working on peptide-based hydrogels for a number of years and have produced about 100 different types, says Jeffrey Hartgerink, a chemist and bioengineer at Rice University. In this paper, we wanted to back up a bit and understand some of the fundamental ways in which they modify biological environments.

The researchers wanted to know specifically how synthetic hydrogels influence the environments inflammatory response. The two-year study offered the first opportunity to test a variety of biocompatible hydrogels for the levels of inflammatory response they trigger.

Usually, we think of inflammation as bad, Hartgerink says. Thats because inflammation is sometimes associated with pain, and nobody likes pain. But the inflammatory response is also extremely important for wound healing and in clearing infection.

We dont want zero inflammation; we want appropriate inflammation, he says. If we want to heal wounds, inflammation is good because it starts the process of rebuilding vasculature. It recruits all kinds of cells that are regenerative to that site.

The labs tested four basic hydrogel typestwo with positive charge and two negativeto see what kind of inflammation they would trigger. They discovered that positively charged hydrogels triggered a much stronger inflammatory response than negatively charged ones.

Among the positive materials, depending on the chemistry generating that charge, we can either generate a strong or a moderate inflammatory response, Hartgerink says. If youre going for wound-healing, you really want a moderate response, and we saw that in one of the four materials.

But if you want to go for a cancer treatment, the higher inflammatory response might be more effective, he says. For something like drug delivery, where inflammation is not helpful, one of the negatively charged materials might be better.

Basically, were laying the groundwork to understand how to develop materials around the inflammatory responses these materials provoke. That will give us our best chance of success.

Researchers at Texas Heart Institute (THI) helped analyze the cellular response to the hydrogels through multidimensional flow cytometry.

The results of this work lay the groundwork for specifically tailoring delivery of a therapeutic by a delivery vehicle that is functionally relevant and predictable, says Darren Woodside, vice president for research and director of the flow cytometry and imaging core at THI. Aside from delivering drugs, these hydrogels are also compatible with a variety of cell types.

One of the problems with stem cell therapies at present is that adoptively transferred cells dont necessarily stay in high numbers at the site of injection, he says. Mixing these relatively inert, negatively charged hydrogels with stem cells before injection may overcome this limitation.

Hartgerink says the work is foundational, rather than geared toward a specific application, but is important to the long-term goal of bringing synthetic hydrogels to the clinic.

We have been speculating about a lot of the things we think are good and true about this material, and we now have more of a sound mechanistic understanding of why they are, in fact, true, Hartgerink says.

The research appears in Biomaterials.

Additional coauthors are from Rice and the Texas Heart Institute. The National Institutes of Health, the Welch Foundation, the Mexican National Council for Science and Technology, the National Science Foundation, and a Stauffer-Rothrock Fellowship supported the research.

Source: Rice University

Originally posted here:
Hydrogel controls inflammation to speed healing - Futurity: Research News

Read More...

OncoImmune Announces Approval of IND Application for ONC-392 The anti-CTLA-4 Antibody that Preserves CTLA-4 Recycling for Better Safety and Efficacy…

January 1st, 2020 7:45 pm

DetailsCategory: AntibodiesPublished on Wednesday, 01 January 2020 12:23Hits: 302

ROCKVILLE, MD, USA I December 30, 2019 I OncoImmune, Inc. announced today that its Investigational New Drug (IND) application for ONC-392, its novel, next generation anti-CTLA-4 antibody, has been approved by the U.S. Food and Drug Administration (FDA). The IND approval enables OncoImmune to begin a Phase 1A/1B clinical trial of ONC-392 that is designed to assess the safety, pharmacokinetics, and efficacy of ONC-392 as a single agent in advanced solid tumors and in combination with anti-PD(L)1 standard of care in Non-

ONC-392 was developed based on the research of OncoImmunes Founders, Drs. Yang Liu and Pan Zheng, who proposed a new theory to improve both the efficacy and safety of immunotherapy drugs. The theory calls for preservation of the CTLA-4 immune checkpoint for safer and more effective immunotherapy. (https://www.sciencedirect.com/science/article/pii/S0165614719302639). This groundbreaking research was published in three papers in Cell Research in 2018 and 2019. The two 2018 papers were recognized with the Sanofi-Cell Research Outstanding Paper Award of 2018 (https://www.nature.com/articles/s41422-019-0248-2).

ONC-392 is OncoImmunes second drug product candidate and the approval of this IND is an important milestone for OncoImmune, said Yang Liu, President and CEO of OncoImmune. Unlike other anti-CTLA-4 antibodies that cause lysosomal degradation of CTLA-4, ONC-392 preserves CTLA-4 recycling and thus maintains CTLA-4 function outside of the tumor microenvironment while allowing more effective CTLA-4-targeted depletion of regulatory T cells within the tumor. The truly novel and differentiated mechanism of action of this drug has the potential to improve therapeutic outcomes while significantly reducing toxicity.

We are very excited to test the potential of this novel antibody in cancer patients, said Pan Zheng, Chief Medical Officer of OncoImmune, Inc.

The CMC development and GMP manufacturing of the drug substance and drug product were performed by WuXi Biologics, a leading global open-access biologics technology platform for the ONC-392 program. Throughout the development program from DNA to IND, we were very impressed by WuXi Biologics expertise and professionalism, and we could not have picked a better partner for this project, said Martin Devenport, OncoImmunes Chief Operating Officer.

About OncoImmune, Inc.

OncoImmune (www.oncoimmune.com) is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases. OncoImmune is based in Rockville, Maryland.

OncoImmunes lead product, CD24Fc, is a novel therapeutic that regulates host inflammatory response to tissue injuries and which has broad implications in the pathogenesis of cancer, autoimmune disease, metabolic syndrome and graft-versus-host disease (GvHD). CD24Fc has completed a Phase IIa trial for the prophylactic treatment of acute Graft versus Host Disease (GvHD) in leukemia patients undergoing hematopoietic stem cell transplantation (HSCT) and resulted in a significant improvement in 180 Day Grade III-IV GVHD Free Survival, the Phase III primary endpoint. CD24Fc prophylaxis also resulted in a reduced relapse and, compared to match controls, CD24Fc demonstrated improvement in Overall Survival, Non-Relapse Mortality and Relapse-Free Survival. A dose-dependent reduction in severe (Grade > 3) mucositis was also observed. A 20 patient open label dose expansion cohort at the recommended clinical dose is fully enrolled and the drug continues to perform very well. A Phase III study is anticipated to start in early 2020.

SOURCE: OncImmune

Read this article:
OncoImmune Announces Approval of IND Application for ONC-392 The anti-CTLA-4 Antibody that Preserves CTLA-4 Recycling for Better Safety and Efficacy...

Read More...

Conway supports man fighting rare double diagnosis of MS, ALS – THV11.com KTHV

January 1st, 2020 7:43 pm

CONWAY, Ark. A Conway man has spent many years living with Multiple Sclerosis, but this year he was also diagnosed with ALS, or Lou Gherigs Disease.

For the Nobles family, every day with their father, Greg, is a treasured moment.

"I was first diagnosed 16 years ago with MS," said Greg Nobles.

Life has been a challenge since, but it was this January when his health began to decline severely.

Greg lost all mobility. After getting treated for his symptoms and not seeing a difference is when neurologists confirmed Greg also suffers from ALS, a nervous system disease weakening muscles with no cure.

"Doctors have never seen a patient with both before, said Bailey Smith, Gregs daughter. Being diagnosed MS first, we got 15 good years with him versus the ALS now.

RELATED: A final fundraiser for the man who boosted the ice bucket challenge

Once active and known as one of the best hairstylist in town, Gregs now homebound hoping for relief from the pain he endures.

"My husband passed away from ALS in 2004, so I know the journey they are going on, said Diana Kirkland, a hair client of Gregs.

Kirkland knew she needed to do something for the Nobles.

She owns Legacy Acres in Conway.

This week shes preparing her space for a fundraising event Friday night to raise money so Greg can receive stem cell therapy, an expensive procedure done in Mexico, but one that will reduce his discomfort.

"If I could just get some mobility back, it's worth it, said Greg.

Greg has already received two rounds of stem cell therapy.

RELATED: Arkansas man raises money for charity by streaming 24-hour gaming session

Fortunately, hes starting to notice relief in his left leg.

But with ALS, hes given 3 to 5 years to live, but with a community coming together to help, his family hopes that love and support will give them more time with him.

"It means everything to us, said Smith. To continue to get stem cells for us, my babies to see my dad keep fighting.

Greg Nobles Fundraising Dinner is at Legacy Acres, 100 Legacy Acres Drive, in Conway on Friday night beginning at 6 p.m.

Everyone is invited. The event will have live music, a silent auction, catered food provided by Catering By S and I.

There will also be a donation table set up for a stem cell therapy fund.

Here is the original post:
Conway supports man fighting rare double diagnosis of MS, ALS - THV11.com KTHV

Read More...

Stem Cell Therapy Market 2020 Analysis by Treatment, Application, Technology, Therapy With Regional Outlook & Forecast To 2025 – The Picayune…

January 1st, 2020 7:42 pm

Growth of Global Stem Cell Therapy Market Size is favored by cumulative factors like development of advanced genome-based cell analysis techniques, soaring awareness of the therapeutic potency of stem cells, detection of novel stem cell lines, and developments in infrastructure related to stem cell banking and processing, and increasing public-private investments for development of stem cell therapies.

In the upcoming years, North America is likely to dominate the global stem cell therapy market share. The U.S. dominates the market which is followed by Canada. Stem cell therapy is powered to cure diseases like diabetes and cancer. There is an increase in occurence of such diseases and higher awareness for the treatment of such diseases is propelling stem cell therapy market. New product innovation & launching, increase in a number of clinical trials for evaluation of the therapeutic potential and higher adoption of these therapies & procedures is fueling market growth. Presence of numerous centers and organization that are engaged in R&D related to new stem cell therapy is likely to led lucrative market growth.

Get more insights at:Global Stem Cell Therapy Market 2020-2025

Europe holds second position in the lucrative market of stem cell therapy. This is attributed to development of efficient & advanced technologies and growing investment in healthcare industry.

The Asia Pacific is projected to exhibit the highest growth in the market. The key countries that are expected to experience fastest development are India and China. The higher adoption of grants by several funding agencies and government for scientific researches is anticipated to stimulate the regional market growth. Investment of leading players for launch and development of newer technologies and increase in healthcare expenditure are also anticipated to up surge the Asia-Pacific market growth of stem cell therapy.

The Middle East & Africa and Latin America regions are expected to show slow growth in the forecast period. Rising awareness about the SC therapies, growing expenditure in the healthcare sector, rapid development in the infrastructure of healthcare and adoption of western technologies and lifestyle is expected to fuel the growth of the stem cell therapy market.

In terms of types of global stem cell therapy market is bifurcated into autologous stem cell therapy and allogeneic stem cell therapy. The segment of allogeneic stem cell therapy is likely to command largest global stem cell therapy market share. This is attributed to easy production scale-up process, escalating commercialization of allogeneic stem cell therapy products, the extensive therapeutic applications of allogeneic stem cells and mounting number of clinical trials related to allogeneic stem cell therapies.

Based on therapeutic application, the global stem cell therapy industry has wide range of categories which includes musculoskeletal disorders, cardiovascular diseases, gastrointestinal diseases, wounds and injuries, surgeries, and other applications. The musculoskeletal disorders sector is anticipated to dominate the global stem cell therapy market by holding largest share. This is attributed to the high prevalence of bone & joint diseases, musculoskeletal disorders, escalating availability of stem cell-based products for the treatment of musculoskeletal disorders and higher patient preference for effective & early treatment strategies.

Get more details about Global Stem Cell Therapy Market:

https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

The global stem cell therapy market is niche industry with soaring global and local companies involved in the commercialization and development of stem cell therapy products. Anterogen Co., Ltd. (South Korea), MEDIPOST Co., Ltd. (South Korea), Osiris Therapeutics, Inc. (U.S.) and Pharmicell Co., Ltd. (South Korea) are the prominent market players of the global stem cell therapy market. The major strategies adopted by leading market players include expansions, partnerships, new product launches and approvals, and agreements to achieve growth in the global stem cell therapy market.

Key segments of Global Stem Cell Therapy Market

Based on cell source, the market has been segmented into,

Based on therapeutic application, the market has been segmented into,

Based on region, the market has been segmented into,

What to expect from the upcoming report on Global Stem Cell Therapy Market:

Future prospects and current trends of the global stem cell therapy market by the end of forecast period (2018-2025)

Information regarding technological progressions as well as innovations taking place in developing economies

Supportive initiatives by government likely to influence the market dynamics

Trends, drivers, opportunities, restraints, challenges and key developments in the market

In-depth analysis of different market segmentations including regional segmentations, and product types

Deep analysis about the competitive landscape of the market and the initiatives by them to improve this market

For Any Query on the Stem Cell Therapy Market:

https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About US:

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX 75204, U.S.A

Phone No.: USA: +1 972-362 -8199 / +91 9665341414

This post was originally published on The Picayune Current

Originally posted here:
Stem Cell Therapy Market 2020 Analysis by Treatment, Application, Technology, Therapy With Regional Outlook & Forecast To 2025 - The Picayune...

Read More...

Stroke Therapeutics Market by Type and Geography – Global Forecast and Analysis 2019-2023 – GlobeNewswire

January 1st, 2020 7:42 pm

Dublin, Dec. 31, 2019 (GLOBE NEWSWIRE) -- The "Stroke Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The stroke therapeutics market analysis considers sales from both ischemic stroke and hemorrhagic stroke types. The analysis also considers the sales of stroke therapeutics in Asia, Europe, North America, and ROW. In 2018, the ischemic stroke therapeutics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as availability of patient assistance programs will play a significant role in the ischemic stroke therapeutics segment to maintain its market position. Also, the global stroke therapeutics market report looks at factors such as high-risk factors for stroke, strong pipeline, and growth of the geriatric population. However, high level of genericization in the market, availability of substitutes, and clinical trial failures may hamper the growth of the stroke therapeutics industry over the forecast period.

Globally, stroke is the second-leading cause of death among adults. The high prevalence of stroke is attributed to the increase in the incidence of ischemic strokes and hemorrhagic strokes, mainly because of the increasing presence of high-risk factors over the years. The major risk factors such as high blood pressure, high cholesterol levels and obesity, heart diseases, and diabetes are increasing the number of strokes that results in several deaths across the world. The risk of stroke also increases due to excessive smoking and alcohol consumption. Such risk factors will lead to the expansion of the global stroke therapeutics market at a CAGR of almost 5% during the forecast period.

The global stroke therapeutics market is expected to benefit from the development of novel therapies, such as stem cell therapies. Owing to the high prevalence of stroke, there is a huge need for safe and innovative novel therapies to treat stroke. Therefore, several companies are developing novel drugs for the treatment of stroke. The development of stem cell therapy will have a major impact on upcoming stroke therapeutics, as it has fewer side effects and regenerative properties. Some of the other novel drugs currently under various stages of development in the stroke therapeutics market are PSD-95 antagonist NA-1 developed by NoNO and 3K3A-APC developed by ZZ Biotech LLC. Such development of novel therapies with fewer side effects is expected to have a positive impact on the overall market growth.

With the presence of several major players, the global stroke therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading stroke therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi.

Also, the stroke therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPEPART 04: MARKET SIZINGPART 05: FIVE FORCES ANALYSISPART 06: MARKET SEGMENTATION BY TYPE

PART 07: CUSTOMER LANDSCAPEPART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORKPART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDSPART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/af16zt

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the rest here:
Stroke Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023 - GlobeNewswire

Read More...

Next Generation Sequencing Market to Exhibit Impressive Growth by 2025 | Agilent Technologies, New England Biolabs, Oxford Nanopore Technolgies…

January 1st, 2020 7:41 pm

Global Next Generation Sequencing (NGS) Market, by Technology (Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Targeted Re-sequencing, and Others), by Application (Drug Discovery, Personalized Medicine and Genetic Screening, Disease Diagnosis, Agriculture and Animal Research, and Others), by End User (Hospital, Research Centers, Pharma and Biotech Firms, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is projected to exhibit a healthy CAGR over the forecast period (2019 2025)

Get Research Insights @Next Generation Sequencing Market Size 2019-2025

Reducing NGS capital cost associated with declining sequencing cost, developments in NGS platforms and developing scenario of reimbursement and regulatory for diagnostic tests based on NGS are projected to fuel the next-generation sequencing market growth. Industry of next-generation sequencing is a market that contains infinite companies present in the production of consumables & kits, instruments and advancement of software to foster the NGS market growth in the coming years.

In addition, the usage of the cloud computing in NGS for the management of data in evolving economies are projected to offer opportunities to the manufacturers of next generation sequencing in the coming future. Developments of technology in cloud computing and data integration, demand for clinical diagnostic and increase in demand for scientific research are the factors that are responsible for the growth of global next generation sequencing market.

In addition, growing acceptance of next generation sequencing technology in several end-users and increasing funds in the activities of research & development is boosting the growth of next-generation sequencing market. Moreover, developing applications of NGS in personalized medicine and food testing is anticipated to drive the next generation sequencing market growth in the coming years. Although, scarcity of the skilled professionals are hindering the next generation sequencing market growth.

Browse Complete Next Generation Sequencing (NGS) Market Report @https://www.adroitmarketresearch.com/industry-reports/next-generation-sequencing-market

Legal and ethical discussions are the part of medical research. Journals and funding agencies are submitting the genomic data from the research contributors to the databases are allowing the investigators for controlling the data. The samples and data are sent from databases without the approval of participant by pushing them at risk. Unidirectional flow of data are creating the sense of distrust and exploitation. As a result, ethical and legal issues are hampering the next generation sequencing market growth.

Development of next generation sequencing market is accredited to the significant reduction in the costs of sequencing. For instance, price of sequencing in 2006 was approximately $15 Billion, which ultimately reduced to $6000 Billion in 2014. Several key players like Illumina and Roche have announced the techniques of sequencing which have decreased the cost related to sequencing.

Growing attention of NGS is projected to fuel the usage of precision medicine in oncology on the basis of research setting to the clinical cancer is increasing the growth of global next generation sequencing industry. Market players are involved in studying the novel and existing tests to create the criteria for medical necessity for medical and clinical policies. Global next generation sequencing market trends are developed understanding of the genetic markers of resistance and virulence offered by next generation sequencing is estimated to boost the demand for the technology of diagnosing the infectious disease.

Make an Enquire to Buy This Report @https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/720

Global next generation sequencing market are end-user, application, technology, product & service and region. On considering the end-user, market is divided into biotechnology & pharmaceutical companies, clinics & hospitals, academic institutes and research centers and more. On the basis of application, market is divided into animal & agricultural research, drug discovery, other diagnostic applications, reproductive health diagnostics, infectious disease diagnostics, cancer diagnostics, diagnostics and much more. Based on technology, market is divided into nanopore sequencing, single-molecule real time sequencing, ion semiconductor sequencing, sequencing by synthesis and more. By product & service, market is divided into bioinformatics, sequencing services, services for NGS platforms, NGS platforms, NGS consumables and pre-sequencing products and services. Bioinformatics further subdivided into NGS storage management & cloud computing solutions, NGS data analysis services and NGS data analysis workbenches & software whereas sequencing services are divided into De Novo and Whole genome sequencing, RNA sequencing, Custom Panels and Exome and Targeted Sequencing. NGS platforms are further sub-divided into Oxford Nanopore Technologies, Pacific Biosciences, ThermoFishcer Scientific, Illumina and others. Pre-sequencing products & services market is divided into quality control, target enrichment & library preparation, size selection, A-tailing, End Repair and DNA fragmentation.

Geographically, regions involved in the global next-generation sequencing (NGS) market analysis are Europe, North America, Asia Pacific and Rest of the World. North America holds the largest global next generation sequencing market share followed by Europe. Asia Pacific is expected to rapidly grow in the coming years.

Key players involved in the next generation sequencing market are Agilent Technologies, New England Biolabs, Oxford Nanopore Technolgies Limited, Thermo Fischer Scientific and more.

Key Segments in the Global Next Generation Sequencing Market are-

By End-User, market is segmented into:

By Application, market is segmented into:

By Technology, market is segmented into:

By Product & Service, market is segmented into:

By Regions market is segmented into:

Early Buyers will Get 10% Discount on This Premium Research now @https://www.adroitmarketresearch.com/contacts/discount/720

What to expect from the Global Next Generation Sequencing Market report?

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

About Adroit Market Research:

Adroit Market Research provide quantified B2B research on numerous opportunistic markets, and offer customized research reports, consulting services, and syndicate research reports. We assist our clients to strategize business decisions and attain sustainable growth in their respective domain. Additionally, we support them with their revenue planning, marketing strategies, and assist them to make decisions before the competition so that they remain ahead of the curve.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

Phone No.: USA: +1 (214) 884-6068 / +91 9665341414

Original post:
Next Generation Sequencing Market to Exhibit Impressive Growth by 2025 | Agilent Technologies, New England Biolabs, Oxford Nanopore Technolgies...

Read More...

Six times SA was at the cutting edge of science in 2019 – TimesLIVE

December 31st, 2019 3:46 pm

From genetics and engineering to astronomy and geoscience, SA has been the setting for a string of major scientific advances this year.

Geneticists found themselves looking backwards as well as forwards in attempts to put right a century-old wrong.

The remains of 11 individuals in the University of Cape Towns skeletal collection were found to have been unethically obtained in the 1920s. It turned out that nine of the individuals were Khoisan farmworkers whose remains were dug up on a farm near Sutherland in the Northern Cape. A major restitution process will lead to their reburial next year.

At the request of the individuals descendants, a multidisciplinary scientific study determined the estimated age, gender and medical condition of each individual and assessed isotopes from bones and teeth to shed light on the their habitat, living conditions and diets.

DNA experts were able to establish ancestral genetic relationships while archaeologists conducted a survey of the cemetery and the disturbed graves. Finally, the individuals faces were recreated.

View original post here:
Six times SA was at the cutting edge of science in 2019 - TimesLIVE

Read More...

Molecular Microbiology Market Insightful Analysis Of Current Scenario And Future Growth Prospect Including Key Players ( BioMerieux, Danaher…

December 31st, 2019 3:46 pm

HTF MI released a new market study on Global Molecular Microbiology Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand in depth analysis. Global Molecular Microbiology Market by Type (, Quantitative PCR Detection Diagnostic Kits & Pathogenic Microorganisms Diagnostic Kits), by End-Users/Application (Human & Veterinary), Industry Size, Organizations, and Region Forecast and outlook to 2025. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, focused opinions, details, and industry certified market data. The research study provides estimates for Global Molecular Microbiology Forecast till 2025*. Some of the key players profiled are Roche, Qiagen, Illumina, Abbott, Hologic, BioMerieux, Danaher (Cepheid), Myriad Genetics, DAAN Gene, Agilent, Genomic Health, BD & Foundation Medicine etc.

Get Access to sample pages @https://www.htfmarketreport.com/sample-report/1618256-global-molecular-microbiology-market-9

The Global Molecular Microbiology market report more focuses on top industry leaders and explores all essentials facets competitive landscape. It explains potent business strategies and approaches, consumption propensity, regulatory policies, recent moves taken by competitors, as well as potential investment opportunities and market threats also. The report emphasis crucial financial details of major manufacturers including year-wise sale, revenue growth, CAGR, production cost analysis, and value chain structure.

In 2018, the Global Molecular Microbiology market size was USD XX and is forecast to reach Million YY USD in 2025, growing at a CAGR of xx%. The objectives of this study is to define, market segment having opportunity, and to project the size of the Molecular Microbiology market based on company, product type, application and key regions.

Besides, the report also covers segment data, including: type segment, industry segment etc. cover different segment market size. Also cover different industries clients information, which is very important for the Major Players. If you need more information, please contact HTF MI at [emailprotected]

**The market is valued based on weighted average selling price (WASP) and includes any applicable taxes on manufacturers. All currency conversions used in the creation of this report have been calculated using constant annual average 2018 currency rates.

Competition Analysis

Global Molecular Microbiology Market Vendor Landscape: The analysts authoring the publication explain the nature and future changes in the competitive scenario of the worldwide companies that are profiled in the publication guide, some of key players that includes in the study are Roche, Qiagen, Illumina, Abbott, Hologic, BioMerieux, Danaher (Cepheid), Myriad Genetics, DAAN Gene, Agilent, Genomic Health, BD & Foundation Medicine

The Study is segmented by following Product Type , Quantitative PCR Detection Diagnostic Kits & Pathogenic Microorganisms Diagnostic Kits

Major applications/end-users industry are as follows Human & Veterinary

Enquire for customization in Report @https://www.htfmarketreport.com/enquiry-before-buy/1618256-global-molecular-microbiology-market-9

Region Segmentation: North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Malaysia, Philippines, Thailand, Vietnam, Europe, Germany, France, UK, Italy, Spain, Russia, Central & South America, Brazil, Rest of Central & South America, Middle East & Africa, GCC Countries, Turkey, Egypt & South Africa

** Customized Report with detailed 2-level country level break-up can also be provided.North America (United States, Canada)South America (Brazil, Argentina, Rest of South America)Asia (China, Japan, India, Korea, RoA)Europe (Germany, United Kingdom, France, Italy, Spain, Russia, Rest of Europe)Others (Middle East, Africa)

In this study, the years considered to estimate the market size of Global Molecular Microbiology are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025

Highly Competitive Market [Perfect Competitive Market C4 Index Beyond 50% of Total Market Share] Focus of the study is to analyse characteristics that affect the nature of competition and pricing. Identifying Influencing factors keeping Global Molecular Microbiology Market Intense, factored with periodic analysis of CR4 & CR8 concentration ratio. In-depth Competitive analysis at product and Strategic business level. Predictive analysis on upcoming trends and changes in consumer behaviour. To analyse the competitive developments, such as new product launch and merger & acquisition, in the Global Molecular Microbiologymarket

Buy full research report @https://www.htfmarketreport.com/buy-now?format=1&report=1618256

Key Stakeholders/Global Reports: Molecular Microbiology Manufacturers Molecular Microbiology Distributors/Traders/Wholesalers Molecular Microbiology Sub-component Manufacturers Industry Association Downstream Vendors

Following would be the Chapters to display the Global Molecular Microbiology market.

Chapter 1, to describe Definition, Specifications and Classification of Molecular Microbiology, Applications of Molecular Microbiology, Market Segment by Regions;Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of Molecular Microbiology, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, to show the Regional Market Analysis that includes North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey & Rest of Middle East & Africa, Molecular Microbiology Segment Market Analysis (by Type);Chapter 7 and 8, to analyze the Molecular Microbiology Segment Market Analysis (by Application) Major Manufacturers Analysis of Molecular Microbiology;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type [, Quantitative PCR Detection Diagnostic Kits & Pathogenic Microorganisms Diagnostic Kits], Market Trend by Application [Human & Veterinary];Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, to analyze the Consumers Analysis of Global Molecular Microbiology;Chapter 12,13, 14 and 15, to describe Molecular Microbiology sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Read Detailed Index of full Research Study at @https://www.htfmarketreport.com/reports/1618256-global-molecular-microbiology-market-9

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us atLinkedIn|Facebook|Twitter

Here is the original post:
Molecular Microbiology Market Insightful Analysis Of Current Scenario And Future Growth Prospect Including Key Players ( BioMerieux, Danaher...

Read More...

Page 765«..1020..764765766767..770780..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick